content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
  filed with the Securities and Exchange Commission on December 10, 2024</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
  No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
  STATES</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
  AND EXCHANGE COMMISSION</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
  D.C. 20549</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
  S-8</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
  STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Onconetix,
  Inc.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
  name of registrant as specified in charter)</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>81-2262816</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
      or Other Jurisdiction of<BR>
      Incorporation or Organization)</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                              Employer</FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
      No.)</FONT></P></TD></TR>
    </TABLE>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>201
                                              E. Fifth Street, Suite 1900</B></FONT></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cincinnati,
      OH</B></FONT></P></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45202</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
      of Principal Executive Offices)</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
      Code)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Onconetix,
      Inc. 2022 Equity Incentive Plan</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Full
      Title of the Plan)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr.
  Ralph Schiess</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interim
  Chief Executive Officer</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Onconetix,
  Inc.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>201
  E. Fifth Street, Suite 1900</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cincinnati,
  OH 45202</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
  and Address of Agent For Service)</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(513)
  620-4101</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone
  Number, Including Area Code of Agent For Service.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Copy
  to:</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Barry
  I. Grossman, Esq.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jessica
  Yuan, Esq.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ellenoff
  Grossman &amp; Schole LLP</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1345
  Avenue of the Americas, 11th Floor</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
  York, New York 10105</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
  (212) 370-1300</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
  by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
  company or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
  &ldquo;smaller reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
      accelerated filer</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
      filer</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
      filer</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
      reporting company</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
      growth company</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
  an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
  with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explanatory
  Note</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Onconetix,
  Inc. (the &ldquo;Registrant&rdquo;) is filing this registration statement on Form S-8 for the purpose of registering an additional 1,390,766&nbsp;
  shares of its common stock, par value $0.00001 per share (the &ldquo;Common Stock&rdquo;), issuable to eligible persons under the 2022
  Equity Incentive Plan (the &ldquo;2022 Plan&rdquo;), which shares are in addition to the shares registered on the Registrant&rsquo;s
  registration statements on Form S-8 filed on June 27, 2022 (File No. 333-265843), November 14, 2022 (File No. 333-268357) and February
  1, 2024 (File No. 333-276824) (collectively, the &ldquo;Prior Registration Statements&rdquo;).</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
  Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted
  in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction
  E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable
  under the 2022 Plan, are incorporated herein by reference and made part of this Registration Statement, except as supplemented, amended,
  and superseded by the information set forth or incorporated by reference herein. Only those items of Form S-8 containing new information
  not contained in the Prior Registration Statements are presented herein.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Registration Statement
  includes, pursuant to General Instruction E to Form S-8, a re-offer prospectus in Part I (the &ldquo;Reoffer Prospectus&rdquo;). The
  Reoffer Prospectus may be utilized for reofferings and resales by certain executive officers and directors listed in the Reoffer Prospectus
  who may be deemed &ldquo;affiliates&rdquo; of the Company on a continuous or a delayed basis in the future of up to 371,596 Common Shares
  issued or to be issued under the 2022 Plan. These shares constitute &ldquo;control securities&rdquo; or &ldquo;restricted securities&rdquo;
  which have been issued prior to or issuable after the filing of this Registration Statement. The Reoffer Prospectus does not contain
  all of the information included in the Registration Statement, certain items of which are contained in schedules and exhibits to the
  Registration Statement, as permitted by the rules and regulations of the SEC. Statements contained in the Reoffer Prospectus as to the
  contents of any agreement, instrument or other document referred to are not necessarily complete. With respect to each such agreement,
  instrument or other document filed as an exhibit to the Registration Statement, we refer you to the exhibit for a more complete description
  of the matter involved, and each such statement shall be deemed qualified in its entirety by this reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
  specified in General Instruction C of Form S-8, until such time as we meet the registrant requirements for use of Form S-3, the number
  of shares of Common Stock to be offered by means of the Reoffer Prospectus, by each of the selling security holders, and any other person
  with whom he or she is acting in concert for the purpose of selling our shares of Common Stock, may not exceed, during any three month
  period, the amount specified in Rule 144(e) of the Securities Act.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise indicated, all share amounts and share prices disclosed herein are presented on a post-split basis, giving effect to
  the one-for-forty (1:40) reverse stock split (the &ldquo;Reverse Stock Split&rdquo;) of all of the outstanding shares of the Company&rsquo;s
  issued and outstanding Common Stock on September 24, 2024. Any financial statements incorporated by reference into this prospectus that
  were filed prior to the Reverse Stock Split present the outstanding shares on a pre-split basis. Financial statements filed after September
  24, 2024 retroactively present the shares on a post-split basis.&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 2; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
  I</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
  REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
  1. Plan Information.*</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
  2. Registrant Information and Employee Plan Annual Information.*</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                              to the Note to Part I on Form S-8, the documents containing the information specified in
                                              Part I of this Registration Statement will be sent or given to plan participants as specified
                                              by Rule 428(b)(1) of the Securities Act of 1934, as amended (the &ldquo;Securities Act&rdquo;).
                                              Such documents are not required to be filed, and are not filed, with the United States Securities
                                              and Exchange Commission either as part of this Registration Statement or as prospectuses
                                              or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and
                                              the documents incorporated by reference in this Registration Statement pursuant to Item 3
                                              of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements
                                              of Section 10(a) of the Securities Act.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REOFFER
  PROSPECTUS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Onconetix,
  Inc.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Up to 371,596 shares
  of Common Stock under the 2022 Equity Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">This
  prospectus relates to the resale of up to 371,596 shares (the &ldquo;Shares&rdquo;) of common stock, par value $0.00001 per share (the
  &ldquo;Common Stock&rdquo;), of Onconetix, Inc., a Delaware corporation (the &ldquo;Company&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;
  or &ldquo;we&rdquo;), which may be offered and sold from time to time by certain stockholders of the Company (the &ldquo;Selling Stockholders&rdquo;)
  who have acquired or will acquire such Shares in connection with the exercise of stock options granted, and with stock or other awards
  made, and with the purchase of stock under, the 2022 Plan. The 2022 Plan is intended to provide incentives which will attract, retain,
  and motivate highly competent persons such as officers, employees, directors, and consultants to our Company by providing them opportunities
  to acquire shares of our Common Stock. Additionally, the 2022 Plan is intended to assist in further aligning the interests of our officers,
  employees, directors and consultants to those of the Company&rsquo;s other stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The persons who are issued such Shares may include our directors, officers,
  employees and consultants, certain of whom may be considered our &ldquo;affiliates&rdquo;. Such persons may, but are not required to,
  sell the Shares they acquire pursuant to this prospectus. If any additional awards are issued to or Shares are purchased by affiliates
  under the 2022 Plan, we will file with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) an update to this prospectus
  naming such person as a selling shareholder and indicating the number of shares such person is offering pursuant to the prospectus. See
  &ldquo;Selling Stockholders&rdquo; on page 12 of this prospectus. Our Common Stock is listed on The Nasdaq Capital Market under the symbol
  &ldquo;ONCO.&rdquo; On December 9, 2024, the closing price of the Common Stock on The Nasdaq Capital Market was $0.7101 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  shares of common stock have experienced extreme volatility in market prices and trading volume since listing. The trading price
  of our common stock has been, and may continue to be, subject to wide price fluctuations in response to various factors, many of which
  are beyond our control, including those described under the heading &ldquo;Risk Factors&rdquo; beginning on page 10 of this prospectus.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
  will not receive any of the proceeds from sales of the Shares by any of the Selling Stockholders. The Shares may be offered from time
  to time by any or all of the Selling Stockholders through ordinary brokerage transactions, in negotiated transactions or in other transactions,
  at such prices as such Selling Stockholder may determine, which may relate to market prices prevailing at the time of sale or be a negotiated
  price. See &ldquo;Plan of Distribution.&rdquo; Sales may be made through brokers or to dealers, who are expected to receive customary
  commissions or discounts. We are paying all expenses of registration incurred in connection with this offering but the Selling Stockholders
  will pay all brokerage commissions and other selling expenses.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Selling Stockholders and participating brokers and dealers may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
  Act, in which event any profit on the sale of shares of those Selling Stockholders and any commissions or discounts received by those
  brokers or dealers may be deemed to be underwriting compensation under the Securities Act.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEE
  &ldquo;RISK FACTORS&rdquo; BEGINNING ON PAGE 10 OF THIS PROSPECTUS FOR A DISCUSSION OF CERTAIN RISKS AND OTHER FACTORS THAT YOU SHOULD
  CONSIDER BEFORE PURCHASING OUR COMMON STOCK.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
  the Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is
  truthful or complete. Any representation to the contrary is a criminal offense.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The date of this prospectus is December 10, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
  OF CONTENTS</B>&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
      No</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
      You Can Find More Information</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">ii<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
      Summary</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1</TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary
      Note Regarding Forward Looking Statements</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">10</TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">13</TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">13</TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>14</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
  should rely only on the information contained in or incorporated by reference into this prospectus or any prospectus supplement. We have
  not authorized any person to give any information or to make any representations other than those contained or incorporated by reference
  in this prospectus, and, if given or made, you must not rely upon such information or representations as having been authorized. This
  prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than our shares of Common
  Stock described in this prospectus or an offer to sell or the solicitation to buy such securities in any circumstances in which such
  offer or solicitation is unlawful. You should not assume that the information we have included in this prospectus is accurate as of any
  date other than the date of this prospectus or that any information we have incorporated by reference is accurate as of any date other
  than the date of the document incorporated by reference regardless of the time of delivery of this prospectus or of any securities registered
  hereunder.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>WHERE
  YOU CAN FIND MORE INFORMATION</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Company is subject to the information requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
  and, in accordance therewith, files reports, proxy statements and other information with the Commission. We are required to file electronic
  versions of those materials with the Commission through the Commission&rsquo;s EDGAR system. The Commission maintains an Internet site
  at http://www.sec.gov, which contains reports, proxy and information statements and other information regarding registrants that file
  electronically with the Commission. You can read and copy the reports, proxy statements and other information filed by the Company with
  the Commission at such Internet site.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
  prospectus constitutes part of a Registration Statement on Form S-8 filed on the date hereof (herein, together with all amendments and
  exhibits, referred to as the &ldquo;Registration Statement&rdquo;) by the Company with the Commission under the Securities Act. This
  prospectus does not contain all of the information set forth in the Registration Statement, certain parts of which we have omitted, in
  accordance with the rules and regulations of the Commission. You should refer to the full Registration Statement for further information
  with respect to the Company and our Common Stock.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
  contained herein concerning the provisions of any contract, agreement or other document are not necessarily complete, and in each instance
  reference is made to the copy of such contract, agreement or other document filed as an exhibit to the Registration Statement or otherwise
  filed with the Commission. Each such statement is qualified in its entirety by such reference. Copies of the Registration Statement together
  with exhibits may be inspected at the offices of the Commission as indicated above without charge and copies thereof may be obtained
  therefrom upon payment of a prescribed fee.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
  person is authorized to give any information or to make any representations, other than those contained in this prospectus, in connection
  with the offering described herein, and, if given or made, such information or representations must not be relied upon as having been
  authorized by the Company or any Selling Stockholder. This prospectus does not constitute an offer to sell, or a solicitation of an offer
  to buy, nor shall there be any sale of these securities by any person in any jurisdiction in which it is unlawful for such person to
  make such offer, solicitation or sale. Neither the delivery of this prospectus nor any sale made hereunder shall under any circumstances
  create an implication that the information contained herein is correct as of any time subsequent to the date hereto.</FONT></P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>PROSPECTUS
  SUMMARY </B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
  SEC allows us to &ldquo;incorporate by reference&rdquo; certain information that we file with the SEC, which means that we can disclose
  important information to you by referring you to those documents. The information incorporated by reference is considered to be part
  of this prospectus, and information that we file later with the SEC will update automatically, supplement and/or supersede the information
  disclosed in this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus
  shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus
  or in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  You should read the following summary together with the more detailed information regarding our company, our Common Stock and our financial
  statements and notes to those statements included in this prospectus.</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
  Company</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a commercial stage
  biotechnology company focused on the research, development, and commercialization of innovative solutions for men&rsquo;s health and oncology.
  Through our recent acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate
  cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (&ldquo;IVDR&rdquo;),
  which we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with Laboratory Corporation of
  America (&ldquo;LabCorp&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also own ENTADFI, an FDA-approved,
  once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate. However, in light of (i)
  the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company&rsquo;s cash runway and indebtedness,
  the Company determined to pause its commercialization of ENTADFI during the first quarter of 2024, as it explores strategic alternatives
  to monetize ENTADFI, such as a potential sale of the ENTADFI assets. To that end, the Company has been working with an investment advisor
  to assist with a potential sale or other transaction of the ENTADFI assets during the second and third quarters of 2024. There is currently
  no plan to resume commercialization of ENTADFI, and as such, if we are not able to consummate a sale or other transaction of the ENTADFI
  assets, we may abandon the assets and destroy our inventory of the product. In addition, as part of cost reduction efforts and in connection
  with our initial pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April&nbsp;30,
  2024, with such individuals to continue assisting the Company on an as-needed, consulting basis. Based on the current circumstances surrounding
  ENTADFI, at June 30, 2024, the ENTADFI assets were fully impaired. Refer to Notes 4 and 5 in the accompanying condensed consolidated financial
  statements incorporated by reference in this prospectus for further discussion. The Company continues to search for a permanent Chief
  Executive Officer and Chief Financial Officer.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently focusing
  our efforts on commercializing Proclarix.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proclarix
  is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient&rsquo;s regular Prostate-Specific
  Antigen (&ldquo;PSA&rdquo;) test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA
  molecules in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many
  other reasons including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing
  for many patients and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant
  resulting in an overdiagnosis and overtreatment that impacts the physician&rsquo;s routine, our healthcare system, and the quality of
  patients&rsquo; lives. Approximately 10% of all men have elevated PSA levels, commonly referred to as the diagnostic &ldquo;grey zone&rdquo;,
  of which only 20 &ndash; 40% present clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult
  to decide if a biopsy is necessary to verify a potential clinically significant cancer diagnosis.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proclarix
  helps doctors and patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear
  and immediate diagnostic support for further treatment decisions. No additional intervention is required, and results are available quickly.
  Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme-linked
  immunosorbent assay (ELISA) standard, which most diagnostic laboratories are already equipped to process.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception in October
  2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development,
  undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel,
  acquiring and developing our technology and now halted vaccine candidates, organizing and staffing our company, performing business planning,
  establishing our intellectual property portfolio and raising capital to support and expand such activities.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the third quarter of
  2023, we halted our vaccine discovery and development programs, and accordingly, we now operate in one segment: commercial. The commercial
  segment was new in the second quarter of 2023 and is currently dedicated to the development and commercialization of Proclarix.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Given Proclarix is CE-marked for sale in
  the European Union, we expect to generate revenue from sales of Proclarix by 2026. Although we anticipate these sales to offset some
  expenses relating to commercial scale up and development, we expect our expenses will increase substantially in connection with our ongoing
  activities, as we:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercialize
                                              Proclarix;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                              additional personnel;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate
                                              as a public company; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain,
                                              maintain, expand, and protect our intellectual property portfolio.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
  rely and will continue to rely on third parties for the manufacturing of Proclarix. We have no internal manufacturing capabilities, and
  we will continue to rely on third parties, of which the main suppliers are single-source suppliers, for commercial products.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have any products
  approved for sale, aside from Proclarix in the European Union, and ENTADFI, from which we have not generated any revenue from product
  sales, and for which we have now abandoned commercialization activities for. We are exploring strategic alternatives to monetize ENTADFI,
  such as a potential sale of the ENTADFI assets. However, if we are not able to consummate a sale or other transaction of the ENTADFI assets,
  we may abandon the assets and destroy our inventory of the product. To date, we have financed our operations primarily with proceeds from
  our sale of preferred securities to seed investors, the initial public offering, the private placements completed during 2022, the proceeds
  received from a warrant exercise in August 2023, the proceeds received from the issuance of debt in January 2024, the proceeds received
  from a warrant exercise in July 2024, and proceeds received from the private placement in October 2024 . We will continue to require significant
  additional capital to commercialize Proclarix, and to fund operations for the foreseeable future. Accordingly, until such time as we can
  generate significant revenue, if ever, we expect to finance our cash needs through public or private equity or debt financings, third-party
  funding and to rely on third-party resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances
  and licensing arrangements, or any combination of these approaches, to support our operations.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred net losses
  since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from
  quarter-to-quarter and year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing
  activities, our expenditures on other research and development activities and commercialization activities. As of September 30, 2024,
  the Company had a working capital deficit of approximately $16.3 million and an accumulated deficit of approximately $86.0 million. In
  addition, as of December 5, 2024, the Company&rsquo;s cash balance was approximately $0.4 million, which is held by the Company&rsquo;s
  foreign subsidiary. The Company believes that its current cash balance is not sufficient to fund its operations through the end of December
  2024, until it can utilize the ELOC, which it entered into in on October 2, 2024, and as such, we will need to raise additional capital
  prior to this to sustain operations. However, based on the terms of the ELOC and the current maximum availability, management has determined
  that the funds readily available under the ELOC will not be sufficient to sustain operations for the next 12 months.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until we generate revenue
  sufficient to support self-sustaining cash flows, if ever, we will need to raise additional capital to fund our continued operations,
  including our product development and commercialization activities related to our current and future products. There can be no assurance
  that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide
  self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The condensed
  consolidated financial statements as of and for the nine months ended September 30, 2024 incorporated by reference in this prospectus
  do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
  of the numerous risks and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses
  or when or if we will be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix,
  we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may
  be unable to continue our operations at planned levels and may be forced to reduce our operations.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
  Developments</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>PIPE
  Financing and ELOC</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">On
  October 2, 2024, the Company entered into, and sold, to six institutional investors (collectively, the &ldquo;PIPE Investors&rdquo;),
  pursuant to a securities purchase agreement an aggregate of 3,499 shares of Series C convertible preferred stock, par value $0.00001 per
  share (&ldquo;Series C Preferred Stock&rdquo;), which includes an issuance of 840 shares of Series C Preferred Stock to the lead investor
  in consideration for the PIPE Investors&rsquo; irrevocable commitment to purchase shares of the Series C Preferred Stock, and warrants
  to purchase 591,856 shares of Common Stock, (together, the &ldquo;PIPE Securities&rdquo;) for aggregate cash proceeds to the Company of
  $2.0 million and net proceeds of $1.9 million. The exercise price of the warrants is $4.38, and the warrants are exercisable six months
  after the issuance date and expire on the third anniversary of the initial exercisability date. </FONT></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">On
  October 2, 2024, the Company entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility with </FONT>Keystone
  Capital Partners, LLC (&ldquo;Keystone&rdquo;)<FONT STYLE="background-color: white">, whereby the Company may offer and sell, from time
  to time at its sole discretion, and whereby Keystone has committed to purchase, up to $25.0 million of the Company&rsquo;s newly issued
  Common Stock, subject to certain limitations. Concurrently with entering into the ELOC Purchase Agreement, the Company also entered into
  a registration rights agreement with Keystone, pursuant to which it agreed to provide Keystone with certain registration rights related
  to the shares issued under the ELOC Purchase Agreement (the &ldquo;ELOC Registration Rights Agreement&rdquo;).</FONT></P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reverse
  Stock Split</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  September 23, 2024, the Company filed an amendment (the &ldquo;Amendment&rdquo;) to the Company&rsquo;s Amended and Restated Certificate
  of Incorporation to effect a Reverse Stock Split of all of the outstanding shares of its issued and outstanding Common Stock at a ratio
  of one-for-forty (1:40). The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern
  Time on September 24, 2024 (the &ldquo;Effective Time&rdquo;). The Company&rsquo;s Common Stock continued to be traded on The Nasdaq
  Capital Market under the symbol ONCO and began trading on a split-adjusted basis when the market opened on Tuesday, September 24, 2024,
  under a new CUSIP number, 68237Q104.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
  the Effective Time, every 40 shares of the Company&rsquo;s issued and outstanding Common Stock were converted automatically into one
  issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and
  without any change in the par value per share.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><BR>
  Conversion of Series A Preferred Stock</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  September 24, 2024, the Company issued an aggregate of 142,749 post-Reverse Stock Split shares of Common Stock to Veru Inc. (&ldquo;Veru&rdquo;),
  following Veru&rsquo;s election to convert all of the 3,000 shares of Series A preferred stock (&ldquo;Series A Preferred Stock&rdquo;)
  of the Company issued to it on September 29, 2023. The Series A Preferred Stock was originally issued to Veru pursuant to an Amendment
  to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion
  of Series B Preferred Stock</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  September 24, 2024, the Company issued an aggregate of 6,741,820 post-Reverse Stock Split shares of Common Stock to certain stockholders
  of the Company (the &ldquo;PMX Converted Shares&rdquo;) who were formerly holders of outstanding capital stock or convertible securities
  (the &ldquo;Sellers&rdquo;) of Proteomedix AG (&ldquo;Proteomedix&rdquo;), pursuant to the automatic conversion of all the 2,696,729
  shares of Series B preferred stock (&ldquo;Series B Preferred Stock&rdquo;) of the Company, which Series B Preferred Stock was originally
  issued to the Sellers on December 15, 2023. The Series B Preferred Stock was originally issued to the Sellers pursuant to a Share Exchange
  Agreement, dated December 15, 2023, between the Company, Proteomedix and the Sellers (the &ldquo;Share Exchange Agreement&rdquo;), and
  were subject to automatic conversion following (i) the Company&rsquo;s receipt of stockholder approval for the issuance of the PMX Converted
  Shares and (ii) the effectiveness of the Reverse Stock Split, which provided for a sufficient number of authorized shares to issue the
  PMX Converted Shares, as contemplated by the Share Exchange Agreement.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Altos
  Units</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  September 24, 2024, pursuant to the Subscription Agreement, dated&nbsp;<FONT STYLE="background-color: white">December 18, 2023, between
  the Company and Altos Venture AG (&ldquo;Altos&rdquo; and such agreement, the &ldquo;Subscription Agreement&rdquo;), the Company issued
  an aggregate of 513,424 units (the &ldquo;Units&rdquo;) to Altos, each Unit comprised of (i) one share of Common Stock and (ii) one pre-funded
  warrant (collectively, the &ldquo;Altos Warrants&rdquo;) to purchase 0.3 shares of Common Stock at an exercise price of $0.04 per share.
  The Altos Warrants were immediately exercisable at any time on or after the date of issuance and had a term of exercise of five (5)&nbsp;years
  from the date of issuance.&nbsp;Additional shares are issuable to Altos to the extent Altos continues to hold Common Stock included in
  the Units and if the VWAP during the 270 days following closing is less than $10.00, as set forth in the Subscription Agreement.</FONT></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
  September 24, 2024, Altos exercised all of the Altos Warrants, and the Company issued to Altos an additional 154,027 shares of Common
  Stock upon such exercise.&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Veru
  Agreement</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Previously, on April 19,
  2023, the Company entered into an asset purchase agreement with Veru (the &ldquo;Veru APA&rdquo;). Pursuant to the terms of the Veru APA,
  the Company agreed to pay to Veru aggregate consideration of $20.0 million, consisting of: (i) $6.0 million paid upon the closing of the
  transaction; (ii) $4.0 million in the form of a non-interest bearing note payable due on September 30, 2023; and (iii) $10.0 million in
  the form of two equal (i.e. each for $5.0 million) non-interest bearing notes payable, which were to be due on April 19, 2024 (the &ldquo;April
  Veru Note&rdquo;) and September 30, 2024 (the &ldquo;September Veru Note&rdquo;), respectively. On September 29, 2023, the parties amended
  (the &ldquo;Veru Amendment&rdquo;) the Veru APA. Pursuant to the Veru Amendment, the $4.0 million note payable originally due on September
  30, 2023, was deemed paid and fully satisfied upon (1) the payment to Veru of $1 million in immediately available funds on September 29,
  2023, and (2) the issuance to Veru by October 3, 2023, of 3,000 shares of Series A Preferred Stock of the Company.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 24, 2024, the Company
  entered into a Forbearance Agreement with Veru (the &ldquo;Original Forbearance Agreement&rdquo;), pursuant to which Veru agreed, among
  other things, to forbear from exercising its rights and remedies under the April Veru Note until March 31, 2025 (the &ldquo;April 2024
  Forbearance Period&rdquo;).</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  September 19, 2024, the Company entered into an Amended and Restated Forbearance Agreement with Veru (the &ldquo;A&amp;R Forbearance
  Agreement&rdquo;) which amends and restates the Original Forbearance Agreement in its entirety. Pursuant to the A&amp;R Forbearance Agreement,
  Veru will forbear from exercising its rights under both the April Veru Note and the September Veru Note, subject to the terms and conditions
  set forth below.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
  to the A&amp;R Forbearance Agreement, the April 2024 Forbearance Period continues to end on the earlier of (a)&nbsp;March&nbsp;31, 2025
  and (b)&nbsp;the occurrence of an Event of Default (as defined in the A&amp;R Forbearance Agreement). The A&amp;R Forbearance Agreement
  also extends the due date for the&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September Veru
  Note until the earlier to occur of: (i) June&nbsp;30, 2025 or (ii) the occurrence of any Event of Default.&nbsp;<FONT STYLE="background-color: white">The
  A&amp;R Forbearance Agreement also effected certain modifications to the payment terms in the Original Forbearance Agreement and amended
  certain terms of the September Veru Note as summarized below.&nbsp;</FONT></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Pursuant
  to the A&amp;R Forbearance Agreement, the Company agreed to make the following required payments (the &ldquo;Required Payments&rdquo;)
  during the April 2024 Forbearance Period first to accrued and unpaid interest under the April Veru Note and then any remainder to the
  outstanding principal amount of the April Veru Note:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
                                              at the rate of 10% per annum shall accrue on any unpaid principal balance of the April Veru
                                              commencing on April 20, 2024 through the date that the outstanding principal balance under
                                              the April Veru Note is paid in full;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></P>
  
  <!-- Field: Page; Sequence: 10; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monthly
                                              payments equal to 25% (increased from 15% in the Original Forbearance Agreement) of (i) the
                                              monthly cash receipts of Proteomedix for the licensing or sale of any products or services,
                                              (ii) monthly cash receipts of the Company or any of its subsidiaries for the sales of Proclarix
                                              anywhere in the world, and (iii) monthly cash receipts of the Company or any of its subsidiaries
                                              for milestone payments or royalties from Labcorp cash receipts of the Company or its subsidiaries
                                              from certain sale or licensing revenues or payments (the Ordinary Cash Revenue&rdquo;), which
                                              increased amount shall begin on October 20, 2024 for cash receipts in September 2024;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment
                                              of 20% (increased from 10% in the Original Forbearance Agreement) of the net proceeds from
                                              certain financing or other transactions outside the ordinary course of business completed
                                              by the Company or any of its subsidiaries during the April 2024 Forbearance Period, which
                                              increased amount will begin for any net proceeds received after September 19, 2024;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15%
                                              of the Ordinary Cash Revenue generated in August 2024 shall be due to Veru on September 26,
                                              2024 (the &ldquo;September Veru Payment&rdquo;); and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                              remaining balance of the April Veru Note will be due at the end of the April 2024 Forbearance
                                              Period.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
  Company and Veru also agreed to the following amendments to the September Veru Note in the A&amp;R Forbearance Agreement:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                              noted above, an extension of the maturity date to June 30, 2025;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                              accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September
                                              Veru Note commencing on October 1, 2024 through the date that the outstanding principal balance
                                              under the September Veru Note is paid in full;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                              amounts owed on the September Veru Note, including but not limited to unpaid principal and
                                              accrued interest, will be paid in cash or, upon the mutual written consent of Veru and the
                                              Company, in shares of the Company&rsquo;s Common Stock or a combination of cash and the Company&rsquo;s
                                              Common Stock;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
                                              full repayment of all principal and interest under the April Veru Note, the Company will
                                              make the Required Payments first towards accrued and unpaid interest under the September
                                              Veru Note and then towards the remaining principal balance payable under the September Veru
                                              Note;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                              the aggregate unpaid principal outstanding under the April Veru Note and the September Veru
                                              Note and all accrued and unpaid interest thereon is repaid in cash on or before December
                                              31, 2024, then the total principal balance under the September Veru Note that will be payable
                                              by the Company in satisfaction of its obligations under the September Veru Note will be reduced
                                              from $5,000,000 to $3,500,000.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  September 26, 2024, Veru and the Company entered into a waiver agreement, pursuant to which Veru postponed the Company&rsquo;s obligation
  to make the September Veru Payment until the earlier of (i) the date upon which the Company consummates a financing transaction in which
  it raises gross proceeds of greater or equal to $1,000,000 and (ii) October 4, 2024. The Company paid the September Veru Payment on October
  10, 2024.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 26, 2024, the
  Company and Veru entered into a waiver and amendment to the A&amp;R Forbearance Agreement (the &ldquo;Amendment&rdquo;), pursuant to which
  Veru agreed to waive the due date for payment of applicable Cash Receipt Payments (as such term is defined in the A&amp;R Forbearance
  Agreement) generated in October 2024 until the Company receives funds of at least $97,000 pursuant to its equity line of credit facility
  with Keystone Capital Partners LLC. In exchange, the Company agreed to increase its payments to be made to Veru out of future financing
  and strategic transactions through June 30, 2025, from 20% to 25% of net proceeds generated from such transactions.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrant
  Inducement</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
  July 11, 2024, the Company, entered into common stock preferred investment options exercise inducement offer letters (the &ldquo;Inducement
  Letter&rdquo;) with certain holders of existing preferred investment options to purchase shares of the Company&rsquo;s common stock at
  the original exercise prices of $101.84 and $43.60 per share, issued on August 11, 2022 and August 2, 2023, respectively, pursuant to
  which the holders agreed to exercise for cash such existing preferred investment options to purchase an aggregate of 186,465 of the Company&rsquo;s
  common stock, at a reduced exercise price of $6.00 per share, in consideration for the Company&rsquo;s agreement to issue new preferred
  investment options (the &ldquo;PIOs&rdquo;) to purchase up to an aggregate of 559,397 shares of the Company&rsquo;s common stock.</FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  transaction closed on July 12, 2024 and the Company received aggregate net proceeds of approximately $0.9 million from the exercise of
  the existing preferred investment options by the holders and the sale of the Inducement PIOs, after deducting placement agent fees and
  other offering expenses payable by the Company.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Company engaged H.C. Wainwright &amp; Co., LLC (&ldquo;Wainwright&rdquo;) to act as its exclusive placement agent in connection with
  the Warrant Inducement and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the existing
  preferred investment options as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the existing preferred
  investment options, plus the reimbursement of up to $85,000 in certain expenses. The Company also agreed to (i) issue to Wainwright or
  its designees an aggregate of 13,054 preferred investment options, and (ii) upon any exercise for cash of the Inducement PIOs, 7.5% of
  the aggregate exercise price and such number of warrant to purchase shares of common stock equal to 7.0% of the aggregate number of such
  shares of common stock underlying the Inducement PIOs that have been exercised, which warrants will have substantially the same terms
  as the Placement Agent Inducement PIOs.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Inducement PIOs have an initial exercise price of $6.00 per share, subject to adjustment; one-third of such preferred investment options
  will expire five years from the date of stockholder approval (September 5, 2024), and the remaining two-thirds will expire twenty-four
  months from such date. The Placement Agent Inducement PIOs have an initial exercise price of $7.50 per share, subject to adjustment,
  and will expire five years from the issuance date.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
  addition, per the terms of the Inducement Letter, the Company agreed not to issue any shares of common stock or common stock equivalents
  or to file any other registration statement with the SEC (in each case, subject to certain exceptions) until the later of (i) the filing
  of a definitive proxy statement on Schedule 14A for the purpose of obtaining the requisite stockholder approval and (ii) 30 days after
  the closing date. The Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement
  Letter) until six months after the closing date (subject to certain exceptions).</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
  Information</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
  were incorporated in Delaware on October 26, 2018. Our principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati,
  Ohio 45202, and our telephone number is (513) 620-4101. Our corporate website address is <I>www.onconetix.com</I>. The information contained
  on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is
  an inactive textual reference only.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt">
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
  Offering</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
      Common Stock:</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,294,734 shares of our Common Stock are outstanding as of December
  5, 2024.</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
      Stock Offered:</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up&#8239;to&#8239;371,596&#8239;shares of Common Stock for sale by the Selling Stockholders (which include our employees, consultants, executive officers
      and directors) for their own account pursuant to the 2022 Plan.</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling
      Stockholders:</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      Selling Stockholders are set forth in the section entitled &ldquo;Selling Stockholders&rdquo; of this reoffer prospectus on page
      12. The amount of securities to be offered or resold by means of the reoffer prospectus by the designated Selling Stockholders
      may not exceed, during any three month period, the amount specified in Rule 144(i).</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
      of proceeds:</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
      will not receive any proceeds from the sale of our Common Stock by the Selling Stockholders. We would, however, receive proceeds
      upon the exercise of the stock options by those who receive options under the Plan and exercise such options for cash. Any cash proceeds
      will be used by us for general corporate purposes.</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
      Factors:</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
      securities offered hereby involve a high degree of risk. See &ldquo;Risk Factors.&rdquo;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
      Capital Market trading symbol:</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ONCO</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>CAUTIONARY
  NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
  prospectus contains &ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws, and that involve significant
  risks and uncertainties. Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo;
  &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo;
  &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense,
  identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and
  may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information
  we have when those statements are made or management&rsquo;s good faith belief as of that time with respect to future events and are
  subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed
  in or suggested by the forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties and assumptions
  in other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports
  on Form 10-Q and our Current Reports on Form 8-K.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
  factors that could cause such differences include, but are not limited to:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              projected financial position and estimated cash burn rate;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              estimates regarding expenses, future revenues and capital requirements;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to continue as a going concern;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              need to raise substantial additional capital to fund our operations;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to commercialize or monetize Proclarix and integrate the assets and commercial operations
                                              acquired in the share exchange with Proteomedix AG (&ldquo;Proteomedix&rdquo;);</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              reliance on third parties, including Labcorp, to develop, market, distribute and sell our
                                              products;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              successful development of our commercialization capabilities, including sales and marketing
                                              capabilities.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to obtain and maintain the necessary regulatory approvals to market and commercialize
                                              our products;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              results of market research conducted by us or others;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to obtain and maintain intellectual property protection for our current products;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to protect our intellectual property rights and the potential for us to incur substantial
                                              costs from lawsuits to enforce or protect our intellectual property rights;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></P>
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              possibility that a third party may claim we or our third-party licensors have infringed,
                                              misappropriated, or otherwise violated their intellectual property rights and that we may
                                              incur substantial costs and be required to devote substantial time defending against claims
                                              against us;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              reliance on third parties, including manufacturers and logistics companies;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              success of competing therapies or diagnostics and products that are or become available;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to successfully compete against current and future competitors;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to expand our organization to accommodate potential growth and our ability to attract,
                                              motivate and retain key personnel;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              potential for us to incur substantial costs resulting from product liability lawsuits against
                                              us and the potential for these product liability lawsuits to cause us to limit our commercialization
                                              of our products;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                              acceptance of our products, the size and growth of the potential markets for our current
                                              products, and our ability to serve those markets; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
                                              in the business of the Company or Proteomedix, which could have an adverse effect on their
                                              respective businesses and financial results.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
  forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;<I>Risk
  Factors</I>.&rdquo; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time.
  It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent
  to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
  statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed
  in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
  statements.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
  should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
  in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
  and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither
  we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation
  to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual
  results or to changes in our expectations.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
  should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
  statement of which this prospectus forms a part with the understanding that our actual future results, levels of activity, performance
  and events and circumstances may be materially different from what we expect.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  </DIV>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 15; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>RISK
  FACTORS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  business involves a high degree of risk and uncertainty, including the following risks and uncertainties:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
  in our common stock involves a high degree of risk. You should carefully consider the following information about these risks before
  deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business,
  reputation, financial condition, results of operations and future growth prospects, as well as our ability to accomplish our strategic
  objectives. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. Additional
  risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and the
  market price of our common stock.</I></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
  is substantial doubt about our ability to continue as a &ldquo;going concern,&rdquo; and we will require substantial additional funding
  to finance our long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or
  terminate some or all of our products and operations.</I></B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company has incurred substantial operating
  losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of September 30, 2024,
  the Company had cash of approximately $0.3&nbsp;million, a working capital deficit of approximately $16.3&nbsp;million and an accumulated
  deficit of approximately $86.0 million. In addition, as of December 5, 2024, the Company&rsquo;s cash balance was approximately $0.4 million,
  which is held by the Company&rsquo;s foreign subsidiary, and the Company has approximately $9.8 million of debt due within the next 12
  months.</P>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We estimate, as of the date of this prospectus,
  that our current cash balance is not sufficient to fund our operations through the end of December, until we can utilize the ELOC. We
  believe that we will need to raise substantial additional capital to fund our continuing operations, satisfy existing and future obligations
  and liabilities, and otherwise support the Company&rsquo;s working capital needs and business activities, including making the remaining
  payments to Veru and the commercialization of Proclarix. Management&rsquo;s plans for funding the Company&rsquo;s operations include generating
  product revenue from sales of Proclarix, which is still subject to further successful development and commercialization activities within
  certain jurisdictions. Management also intends to secure additional required funding through equity or debt financings if available, and
  to utilize the <FONT STYLE="background-color: white">ELOC </FONT>on an as-needed basis to assist with the paydown of the debentures and
  to fund current operating needs, subject to certain restrictions and beneficial ownership constraints. However, based on the terms of
  the ELOC and the current maximum availability, management has determined that the funds readily available under the ELOC will not be sufficient
  to sustain operations for the next 12 months. In addition, there are currently no other commitments in place for further financing nor
  is there any assurance that such financing will be available to the Company on favorable terms, if at all. This creates significant uncertainty
  whether the Company will have the funds available to be able to sustain its long-term operations and expand commercialization of Proclarix.
  If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization
  of future product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient
  to sustain operations and meet its obligations, or, if it is required to, file for bankruptcy.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
  conditions raise substantial doubt about the Company&rsquo;s ability to continue as a going concern for a period of time within one
  year from the issuance of the condensed consolidated financial statements. Our future capital requirements will depend on many
  factors, including:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; font: 11pt Calibri,sans-serif">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font: 11pt Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="font: 11pt Calibri,sans-serif; text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">the costs of future development and commercialization activities, including product manufacturing, marketing, sales, royalties, and distribution, for Proclarix and other products for which we have received or will receive marketing approval;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              ability to maintain existing, and establish new, strategic collaborations, licensing or other
                                              arrangements and the financial terms of any such agreements, including the timing and amount
                                              of any future milestone, royalty, or other payments due under any such agreement;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                              product liability or other lawsuits related to our products;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              expenses needed to attract, hire, and retain skilled personnel;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              revenue, if any, received from commercial sales of Proclarix or other products for which
                                              we may receive marketing approval;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 16; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property
                                              portfolio, including the amount and timing of any payments we may be required to make, or
                                              that we may receive, in connection with licensing, preparing, filing, prosecuting, defending,
                                              and enforcing our patents or other intellectual property rights; and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              costs of operating as a public company.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to raise additional funds
  will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional funding
  will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional
  capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce, or terminate our business activities.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify"><B><I>We owe a significant amount of money to Veru, which
  funds we do not have. Veru may take action against us to enforce its rights to payment in the future, which could have a material adverse
  effect on us and our operations.</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to recent financial constraints,
  the Company may be unable to timely pay amounts due to Veru, from whom we purchased ENTADFI in April 2023. We may not have sufficient
  funds to pay amounts due to Veru in the near term, if at all, including but not limited to $10 million, $5 million of which was due on
  April 19, 2024 and is subject to certain forbearance terms, and $5 million of which was due on September 30, 2024 and is subject to certain
  forbearance terms. On April 24, 2024, Veru agreed to forbear its rights and remedies until March 31, 2025 with respect to, among other
  things, our inability to pay amounts due on April 19, 2024. Additionally, on September 19, 2024 and November 26, 2024, Veru agreed to
  forbear its rights and remedies until June 30, 2025 with respect to, among other things, our inability to certain pay amounts due on September
  30, 2024 and November 20, 2024. However, Veru may take future action against us, including filing legal proceedings against us seeking
  amounts due and interest accrued or attempting to terminate its relationship with us. If Veru were to take legal action against us, we
  may be forced to scale back our business plan and/or seek bankruptcy protection. We may be subject to litigation and damages for our failure
  to pay amounts due to Veru, and may be forced to pay interest and penalties, which funds we do not currently have. We are currently considering
  strategic options for ENTADFI, including a potential sale or abandonment, and plan to seek funding to support our operations, and to pay
  amounts due to Veru, through a combination of equity offerings, debt financing or other capital sources, including potential collaborations,
  licenses, sales, and other similar arrangements, which may not be available on favorable terms, if at all. The sale of additional equity
  or debt securities, if accomplished, may result in dilution to our stockholders. Furthermore, any revenue or financing proceeds that we
  are required to pay to Veru will detract from our ability to use such funds to support our operations.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
  current liabilities are significant, and if those to whom we owe accounts payable, such as Veru, IQVIA or other creditors or vendors,
  were to demand payment, we would be unable to pay.</I></B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of September 30, 2024, we had
  total current liabilities of approximately $17.4 million, including accounts payable of approximately $4.1 million, accrued expenses of
  approximately $1.3 million, the related party subscription liability of $1.8 million, and approximately $9.8 million (net of discounts)
  related to notes payable, primarily due to Veru. As of the same date, we had cash of only $0.3 million. We are currently considering strategic
  options for ENTADFI, including a potential sale or abandonment, and plan to seek funding to support our operations. However, the level
  of our current liabilities may make it more difficult for us to obtain adequate financing on favorable terms, if at all. If those to whom
  these payments are due were to demand immediate payment, as they are entitled to do, and we are not able to make the required payments,
  we would be subject to liability if our creditors chose to enforce their rights, which could result in our bankruptcy and insolvency.
  Under such a scenario, our assets would be distributed to our creditors, leaving nothing to be distributed to our stockholders.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
  are dependent on third parties, including Labcorp, to develop market, distribute and sell our products.</I></B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  ability to receive revenues is dependent upon the sales and marketing efforts of co-marketing partners and third-party distributors.
  In particular, the development and commercialization of Proclarix in the United States is being pursued by Labcorp, pursuant to an exclusive
  license agreement that grants Labcorp the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp
  using Proteomedix&rsquo;s intellectual property covered by the license, in the United States for identification, screening, staging,
  predisposition, diagnosis, prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. However, we do not
  have control over Labcorp&rsquo;s development and commercialization of Proclarix, and there can be no guarantee that Labcorp will continue
  to advance development and commercialization efforts, or that Labcorp will successfully commercialize Proclarix in the United States.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labcorp
  may terminate or seek to renegotiate the terms of this agreement, which could adversely affect our business operations and financial
  condition. If Labcorp terminates the agreement or demands terms that are less favorable to us, we may experience disruptions in our product
  development and commercialization efforts, potentially leading to a loss of revenue and market share.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
  if Labcorp is unable to commercialize Proclarix in the United States, and we fail to reach an agreement with any other commercialization
  partner, or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact
  on our business, financial condition, and results of operations.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 17; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>SELLING
  STOCKHOLDERS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  following table sets forth (a) the name and position or positions with the Company of each Selling Stockholder; (b) the aggregate of
  (i) the number of shares of Common Stock held by each Selling Stockholder as of the date of this prospectus and (ii) the number of shares
  issuable upon exercise of options granted to each Selling Stockholder under the 2022 Plan that are being registered pursuant to this
  Registration Statement for resale by each Selling Stockholder as of the date of this prospectus; (c) the number of shares of Common Stock
  issuable upon exercise of options that each Selling Stockholder may offer for sale from time to time pursuant to this prospectus, whether
  or not such Selling Stockholder has a present intention to do so; and (d) the number of shares of Common Stock to be beneficially owned
  by each Selling Stockholder following the sale of all shares that may be so offered pursuant to this prospectus, assuming no other change
  in ownership of Common Stock by such Selling Stockholder after the date of this prospectus. Unless otherwise indicated, beneficial ownership
  is direct and the person indicated has sole voting and investment power.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Selling Stockholders may, from time to time, resell all, a portion or none of the shares of our Common Stock covered by this reoffer
  prospectus.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inclusion
  of an individual&rsquo;s name in the table below does not constitute an admission that such individual is an &ldquo;affiliate&rdquo;
  of the Company.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal<BR> Position with<BR> the Company</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Owned<BR> Prior to Resale</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;of <BR> Shares<BR> Offered</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Beneficially Owned<BR> After Resale</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&nbsp;(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><SUP>&nbsp;</SUP></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent&nbsp;(2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">for&nbsp;Resale</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent&nbsp;(3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; width: 20%; text-align: left">Ralph Schiess</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 34%; text-align: left">Interim Chief Executive Officer, <BR> Chief Science Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">672,967</TD><TD STYLE="width: 1%; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">7.9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">177,464</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">495,503</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">6.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Christian Br&uuml;hlmann</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">Chief Strategy Officer</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">611,374</TD><TD STYLE="text-align: left"><SUP>(4)</SUP></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">177,464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">433,910</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.2</TD><TD STYLE="text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Simon Tarsh</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,578</TD><TD STYLE="text-align: left"><SUP>(5)</SUP></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Timothy Ramdeen</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,536</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">James Sapirstein</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,741</TD><TD STYLE="text-align: left"><SUP>(7)</SUP></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,423</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="vertical-align: top; text-align: left">Thomas Meier</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="text-align: left"><SUP>(8)</SUP></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,318</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: left">Ajit Singh</TD><TD>&nbsp;</TD>
      <TD>Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,396</TD><TD STYLE="text-align: left"><SUP>(9)</SUP></TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                              than 1%.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                              number of shares owned prior to resale by each Selling Stockholder shares of Common Stock
                                              owned on or about the date hereof by the Selling Stockholders and shares of Common Stock
                                              that are issued or to be issued, or which may be acquired upon the exercise of stock options
                                              issued or to be issued, or vesting of restricted stock awards issued or to be issued, pursuant
                                              to the 2022 Plan.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; font: 11pt Calibri,sans-serif"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="font: 11pt Calibri,sans-serif; text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Percentage is computed with reference to 8,294,734 shares of our Common Stock outstanding as of December 5, 2024. In addition, we deemed outstanding shares of Common Stock subject to options or warrants held by each person for purposes of computing the percentage of ownership for such person. However, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes&nbsp;177,464 restricted stock units.</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes&nbsp;177,464 restricted stock units.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes (i) options to purchase 101 shares of Common Stock and (ii) 3,318 shares of restricted stock that vest on August 31, 2025.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes (i) options to purchase 59 shares of Common Stock and (ii) 3,318 shares of restricted stock that vest on August 31, 2025.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; font: 11pt Calibri,sans-serif; text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">(7)</FONT></TD>
      <TD STYLE="font: 11pt Calibri,sans-serif; text-align: justify"><FONT STYLE="font-family: Times New Roman,serif; font-size: 10pt">Includes (i) options to purchase 1,264 shares of Common Stock (929 of which are vested within 60 days of December 5, 2024 and (ii) 3,318 shares of restricted stock that vest on August 31, 2025.</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 3,318 shares of restricted stock that vest on August 31, 2025.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 3,318 shares of restricted stock that vest on August 31, 2025.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Company may supplement this prospectus from time to time as required by the rules of the Commission to include certain information concerning
  the security ownership of the Selling Stockholders or any new Selling Stockholders, the number of securities offered for resale and the
  position, office or other material relationship which a Selling Stockholder has had within the past three years with the Company or any
  of its predecessors or affiliates.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 18; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>USE
  OF PROCEEDS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
  will not receive any proceeds from the resale of our Common Stock by the Selling Stockholders pursuant to this prospectus. However, we
  will receive the exercise price of any Common Stock issued to the Selling Stockholders upon cash exercise by them of their options. We
  would expect to use these proceeds, if any, for general working capital purposes. We have agreed to pay the expenses of registration
  of these shares.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>PLAN
  OF DISTRIBUTION</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
  this section of the prospectus, the term &ldquo;Selling Stockholder&rdquo; means and includes:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.15pt; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.15pt; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
      persons identified in the table above as the Selling Stockholders;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.15pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.15pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.3pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">those
      persons whose identities are not known as of the date hereof but may in the future be eligible to receive options under the 2022
      Plan; and</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.55pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 1.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
      of the donees, pledgees, distributees, transferees or other successors in interest of those persons referenced above who may: (a)
      receive any of the shares of our Common Stock offered hereby after the date of this prospectus and (b) offer or sell those shares
      hereunder.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  shares of our Common Stock offered by this prospectus may be sold from time to time directly by the Selling Stockholders. Alternatively,
  the Selling Stockholders may from time to time offer such shares through underwriters, brokers, dealers, agents or other intermediaries.
  The Selling Stockholders as of the date of this prospectus have advised us that there were no underwriting or distribution arrangements
  entered into with respect to the Common Stock offered hereby. The distribution of the Common Stock by the Selling Stockholders may be
  effected: in one or more transactions that may take place on The Nasdaq Capital Market (including one or more block transactions) through
  customary brokerage channels, either through brokers acting as agents for the Selling Stockholders, or through market makers, dealers
  or underwriters acting as principals who may resell these shares on The Nasdaq Capital Market; in privately-negotiated sales; by a combination
  of such methods; or by other means. These transactions may be effected at market prices prevailing at the time of sale, at prices related
  to such prevailing market prices or at other negotiated prices. Usual and customary or specifically negotiated brokerage fees or commissions
  may be paid by the Selling Stockholders in connection with sales of our Common Stock.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Selling Stockholders may enter into hedging transactions with broker-dealers in connection with distributions of the shares or otherwise.
  In such transactions, broker-dealers may engage in short sales of the shares of our Common Stock in the course of hedging the positions
  they assume with the Selling Stockholders. The Selling Stockholders also may sell shares short and redeliver the shares to close out
  such short positions. The Selling Stockholders may enter into option or other transactions with broker-dealers which require the delivery
  to the broker-dealer of shares of our Common Stock. The broker-dealer may then resell or otherwise transfer such shares of Common Stock
  pursuant to this prospectus.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
  the time a particular offering of shares of our Common Stock is made, a prospectus supplement, if required, will be distributed, which
  will set forth the name of the Selling Stockholders, the aggregate amount of shares of our Common Stock being offered and the terms of
  the offering, including, to the extent required, (1) the name or names of any underwriters, broker-dealers or agents, (2) any discounts,
  commissions and other terms constituting compensation from the Selling Stockholders and (3) any discounts, commissions or concessions
  allowed or reallowed to be paid to broker-dealers.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Selling Stockholders also may lend or pledge shares of our Common Stock to a broker-dealer. The broker-dealer may sell the shares of
  Common Stock so lent, or upon a default the broker-dealer may sell the pledged shares of Common Stock pursuant to this prospectus.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Selling Stockholders will act independently of us in making decisions with respect to the timing, manner, and size of each resale or
  other transfer. There can be no assurance that the Selling Stockholders will sell any or all of the shares of our Common Stock under
  this prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the shares
  of our Common Stock by other means not described in this prospectus. In addition, any Shares covered by this prospectus that qualify
  for sale under Rule 144 of the Securities Act may be sold under Rule 144 rather than under this prospectus.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Selling Stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters
  or broker-dealers regarding the sale of their securities. There is no underwriter or coordinating broker acting in connection with the
  proposed sale of shares of Common Stock the Selling Stockholders.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
  the shares of Common Stock covered by this prospectus are not currently being underwritten, the Selling Stockholders or their underwriters,
  brokers, dealers or other agents or other intermediaries, if any, that may participate with the selling security holders in any offering
  or distribution of Common Stock may be deemed &ldquo;underwriters&rdquo; within the meaning of the Securities Act and any profits realized
  or commissions received by them may be deemed underwriting compensation thereunder.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
  applicable rules and regulations under the Exchange Act, any person engaged in a distribution of shares of the Common Stock offered hereby
  may not simultaneously engage in market making activities with respect to the Common Stock for a period of up to five days preceding
  such distribution. The Selling Stockholders will be subject to the applicable provisions of the Exchange Act and the rules and regulations
  promulgated thereunder, including without limitation Regulation M, which provisions may limit the timing of purchases and sales by the
  Selling Stockholders.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
  order to comply with certain state securities or blue sky laws and regulations, if applicable, the Common Stock offered hereby will be
  sold in such jurisdictions only through registered or licensed brokers or dealers. In certain states, the Common Stock may not be sold
  unless they are registered or qualified for sale in such state, or unless an exemption from registration or qualification is available
  and is obtained.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
  will bear all costs, expenses and fees in connection with the registration of the Common Stock offered hereby. However, the Selling Stockholders
  will bear any brokerage or underwriting commissions and similar selling expenses, if any, attributable to the sale of the shares of Common
  Stock offered pursuant to this prospectus. We have agreed to indemnify the Selling Stockholders against certain liabilities, including
  liabilities under the Securities Act, or to contribute to payments to which any of those security holders may be required to make in
  respect thereof.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>LEGAL
  MATTERS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  validity of the securities being offered herein has been passed upon for us by Ellenoff Grossman &amp; Schole LLP, New York, New York.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>
  
  <!-- Field: Page; Sequence: 20; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCLOSURE
  OF COMMISSION POSITION ON</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEMNIFICATION
  FOR SECURITIES LAWS VIOLATIONS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
  145 of the DGCL inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made
  a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation)
  by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the
  request of the corporation as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including
  attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such
  action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests
  of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
  Similar indemnity is authorized for such persons against expenses (including attorneys&rsquo; fees) actually and reasonably incurred
  in connection with the defense or settlement of any such threatened, pending or completed action or suit if such person acted in good
  faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and provided further that
  (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable to the corporation. Any
  such indemnification may be made only as authorized in each specific case upon a determination by the stockholders or disinterested directors
  or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee has met the applicable standard
  of conduct.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
  145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
  or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
  corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his
  status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies
  insuring our officers and directors against certain liabilities for actions taken in such capacities, including liabilities under the
  Securities Act.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
  102(b)(7) of the DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal
  liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided
  that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director&rsquo;s duty of loyalty
  to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing
  violation of law, (iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption)
  or (iv) for any transaction from which the director derived an improper personal benefit.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article
  6 of the bylaws of the Company contains provisions which are designed to provide mandatory indemnification of directors and officers
  of the Company to the full extent permitted by law, as now in effect or later amended. The bylaws further provide that, if and to the
  extent required by the DGCL, an advance payment of expenses to a director or officer of the Company that is entitled to indemnification
  will only be made upon delivery to the Company of an undertaking, by or on behalf of the director or officer, to repay all amounts so
  advanced if it is ultimately determined that such director is not entitled to indemnification.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 21; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
  should rely only on the information contained in this document. We have not authorized anyone to provide you with information that is
  different. This document may only be used where it is legal to sell these securities. The information in this document may only be accurate
  on the date of this document.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
  risks and uncertainties not presently known or that are currently deemed immaterial may also impair our business operations. The risks
  and uncertainties described in this document and other risks and uncertainties which we may face in the future will have a greater impact
  on those who purchase our common stock. These purchasers will purchase our common stock at the market price or at a privately negotiated
  price and will run the risk of losing their entire investment.</B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONCONETIX,
  INC.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>371,596 Shares of</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
  Stock</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 10, 2024</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></FONT></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 22 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
  II </B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
  REQUIRED IN THE REGISTRATION STATEMENT </B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
  3. Incorporation of Documents by Reference.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  following documents filed with the Commission by the Registrant pursuant to the Securities Act and the Securities Exchange Act of 1934,
  as amended (the &ldquo;Exchange Act&rdquo;), are hereby incorporated by reference in this registration statement:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea0201701-10k_onconetix.htm">Form 10-K</A> for the fiscal year ended December 31, 2023, as filed with the
                                              SEC on April 11, 2024</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
      <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024045172/ea0206102-10q_onconetix.htm">May 20, 2024</A>, for the quarter ended June 30, 2024, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024073545/ea0212631-10q_onconetix.htm">August 29, 2024</A> and for the quarter ended September 30, 2024, as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024107088/ea0223979-10q_onconetix.htm">December 10, 2024</A>;</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
  Reports on Form 8-K filed on each of <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024003413/ea191591-8k_onconetix.htm">January
  12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024004855/ea191886-8k_onconetix.htm">January 19, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024007414/ea192391-8k_onconetix.htm">January 29, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024012608/ea193470-8k_onconetix.htm">February
  12, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024012876/ea193550-8k_onconetix.htm">February 13, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024017544/ea0200807-8ka2_onconetix.htm">February 27, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024031167/ea0203476-8k_onconetix.htm">April
  8, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024036645/ea0204751-8k_oncone.htm">April 26, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024042369/ea0205933-8k_oncone.htm">May 13, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024052469/ea0207635-8k_onconetix.htm">June
  13, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024052976/ea0207933-8ka1_onconet.htm">June 14, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024060635/ea0209277-8k_onconetix.htm">July 11, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024061151/ea0209387-8k_onconetix.htm">July
  15, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024066108/ea0210771-8k_onconetix.htm">August 7, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024075008/ea0213181-8k_onconetix.htm">September 3, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024075697/ea0213522-8k_onconetix.htm">September
  5, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024077457/ea0214181-8k_onconetix.htm">September 11, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024080705/ea0215265-8k_onconetix.htm">September 20, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea0215560-8k_onconetix.htm">September
  24, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea0216649-8k_onconetix.htm">October 3, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024086655/ea0217249-8ka1_onconetix.htm">October 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024089338/ea0218143-8k_onconetix.htm">October
  21, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024105072/ea0223490-8k_onconetix.htm">December 3, 2024</A></FONT>;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                              <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024064077/ea0210311-def14a_onconetix.htm">Definitive Proxy Statement</A>, as filed with the SEC on August 1, 2024, and the <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024075010/ea0213181-8k_onconetix.htm">supplemental proxy materials</A> filed with the SEC on September 3, 2024; and</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                              description of our securities registered under Section 12 of the Exchange Act as filed as
                                              <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex4-2_onconetix.htm">Exhibit 4.2</A> on our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea0201701-10k_onconetix.htm">Form 10-K</A> for the year ended December 31, 2023, as filed
                                              with the SEC on April 11, 2024.</FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
  documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of
  this registration statement (except for any portions of the Registrant&rsquo;s current reports on Form 8-K furnished pursuant to Item
  2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective
  amendment to this registration statement indicating that all securities offered have been sold or which deregisters all securities then
  remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date
  of filing of such documents.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
  statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document
  which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified
  or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
  8. Exhibits.</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  following exhibits are filed as part of this registration statement:</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incorporated
      by Reference</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
      No.</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 52%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filing
      Date</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390021056861/fs12021a1ex4-1_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Common Stock Certificate.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
      8, 2021</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024032225/ea020170101ex4-2_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Registered Securities.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-K</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
      11, 2024</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000101376223000742/ea186204ex3-1_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Preferred Stock.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
      3, 2023</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024060635/ea020927701ex4-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Inducement PIO.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
      11, 2024</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024081482/ea021556001ex4-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Altos Warrants.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;24,&nbsp;2024</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex4-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
      3, 2024</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390024084866/ea021664901ex3-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Designation of Series C Preferred Stock.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
      3, 2024</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ea022008001ex5-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Ellenoff Grossman &amp; Schole LLP as to the legality of the securities being registered.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-2_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Equity Incentive Plan.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
      29, 2021</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-4_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
      6, 2022</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-5_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
      6, 2022</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-6_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
      6, 2022</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390022000991/fs12022a5ex10-7_bluewater.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
      6, 2022</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ea022008001ex23-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of CBIZ CPAs P.C.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ea022008001ex23-2_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of EisnerAmper LLP.</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea022008001ex23-3_onconetix.htm">Consent of BDO AG.</A></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="ea022008001ex5-1_onconetix.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Ellenoff Grossman &amp; Schole (included as part of Exhibit 5.1 hereto).</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#poa"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on signature page to this Registration Statement).</FONT></A></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea022008001ex-fee_onconetix.htm">Filing Fee Table.</A></FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                              herewith.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 24; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa"></A>SIGNATURES</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
  of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the
  requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
  duly authorized, on December 10, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ONCONETIX,
      INC.</B></FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
      Dr. Ralph Schiess</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
      Ralph Schiess</FONT></TD></TR>
    <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
      <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interim
      Chief Executive Officer</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
  OF ATTORNEY</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>KNOW
  ALL MEN BY THESE PRESENTS</B>, that we, the undersigned officers and directors of Onconetix, Inc., a Delaware corporation, do hereby
  constitute and appoint each of Dr. Ralph Schiess and Karina Fedasz as his or her true and lawful attorney-in-fact and agent, with full
  power of substitution and re-substitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all
  amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement
  and any subsequent registration statement filed by the registrant pursuant to Rule 462(b) of the Securities Act of 1933, as amended,
  which relates to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith,
  with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform
  each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might
  or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may
  lawfully do or cause to be done by virtue hereof.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
  to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
  and on the dates indicated.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 43%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Ralph Schiess</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Interim Chief Executive Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Ralph Schiess</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Karina M. Fedasz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Interim Chief Financial Officer</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Karina M. Fedasz</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ James Sapirstein</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Chairman of the Board and Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">James Sapirstein</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas Meier</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Thomas Meier</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Timothy Ramdeen</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Timothy Ramdeen</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Ajit Singh</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Ajit Singh</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Simon Tarsh</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">December 10, 2024</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Simon Tarsh</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>
  
  <!-- Field: Page; Sequence: 25; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0220080-s8_onconetix.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 298266}]
metadata_filer: {"company-data": {"conformed-name": "Onconetix, Inc.", "cik": "0001782107", "assigned-sic": "2834", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-283726", "film-number": "241540094"}, "business-address": {"street1": "201 E. FIFTH STREET", "street2": "SUITE 1900", "city": "CINCINNATI", "state": "OH", "zip": "45202", "phone": "513-620-4101"}, "mail-address": {"street1": "201 E. FIFTH STREET", "street2": "SUITE 1900", "city": "CINCINNATI", "state": "OH", "zip": "45202"}, "former-company": [{"former-conformed-name": "Blue Water Biotech, Inc.", "date-changed": "20230424"}, {"former-conformed-name": "Blue Water Vaccines Inc.", "date-changed": "20190710"}]}
text: As
  filed with the Securities and Exchange Commission on December 10, 2024
  Registration
  No. 333-
  UNITED
  STATES
  SECURITIES
  AND EXCHANGE COMMISSION
  Washington,
  D.C. 20549
  FORM
  S-8
  REGISTRATION
  STATEMENT UNDER THE SECURITIES ACT OF 1933
  Onconetix,
  Inc.
  (Exact
  name of registrant as specified in charter)
  Delaware
  81-2262816
  (State
      or Other Jurisdiction of
  Incorporation or Organization)
  (IRS
                                              Employer
  Identification
      No.)
  201
                                              E. Fifth Street, Suite 1900
  Cincinnati,
      OH
  45202
  (Address
      of Principal Executive Offices)
  (Zip
      Code)
  Onconetix,
      Inc. 2022 Equity Incentive Plan
  (Full
      Title of the Plan)
  Dr.
  Ralph Schiess
  Interim
  Chief Executive Officer
  Onconetix,
  Inc.
  201
  E. Fifth Street, Suite 1900
  Cincinnati,
  OH 45202
  (Name
  and Address of Agent For Service)
  (513)
  620-4101
  Telephone
  Number, Including Area Code of Agent For Service.
  Copy
  to:
  Barry
  I. Grossman, Esq.
  Jessica
  Yuan, Esq.
  Ellenoff
  Grossman & Schole LLP
  1345
  Avenue of the Americas, 11th Floor
  New
  York, New York 10105
  Telephone:
  (212) 370-1300
  Indicate
  by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
  company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"
  "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):
  Large
      accelerated filer
  ☐
  Accelerated
      filer
  ☐
  Non-accelerated
      filer
  ☒
  Smaller
      reporting company
  ☒
  Emerging
      growth company
  ☒
  If
  an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
  with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  Explanatory
  Note
  Onconetix,
  Inc. (the "Registrant") is filing this registration statement on Form S-8 for the purpose of registering an additional 1,390,766 
  shares of its common stock, par value $0.00001 per share (the "Common Stock"), issuable to eligible persons under the 2022
  Equity Incentive Plan (the "2022 Plan"), which shares are in addition to the shares registered on the Registrant's
  registration statements on Form S-8 filed on June 27, 2022 (File No. 333-265843), November 14, 2022 (File No. 333-268357) and February
  1, 2024 (File No. 333-276824) (collectively, the "Prior Registration Statements").
  This
  Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted
  in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction
  E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable
  under the 2022 Plan, are incorporated herein by reference and made part of this Registration Statement, except as supplemented, amended,
  and superseded by the information set forth or incorporated by reference herein. Only those items of Form S-8 containing new information
  not contained in the Prior Registration Statements are presented herein.
  This Registration Statement
  includes, pursuant to General Instruction E to Form S-8, a re-offer prospectus in Part I (the "Reoffer Prospectus"). The
  Reoffer Prospectus may be utilized for reofferings and resales by certain executive officers and directors listed in the Reoffer Prospectus
  who may be deemed "affiliates" of the Company on a continuous or a delayed basis in the future of up to 371,596 Common Shares
  issued or to be issued under the 2022 Plan. These shares constitute "control securities" or "restricted securities"
  which have been issued prior to or issuable after the filing of this Registration Statement. The Reoffer Prospectus does not contain
  all of the information included in the Registration Statement, certain items of which are contained in schedules and exhibits to the
  Registration Statement, as permitted by the rules and regulations of the SEC. Statements contained in the Reoffer Prospectus as to the
  contents of any agreement, instrument or other document referred to are not necessarily complete. With respect to each such agreement,
  instrument or other document filed as an exhibit to the Registration Statement, we refer you to the exhibit for a more complete description
  of the matter involved, and each such statement shall be deemed qualified in its entirety by this reference.
  As
  specified in General Instruction C of Form S-8, until such time as we meet the registrant requirements for use of Form S-3, the number
  of shares of Common Stock to be offered by means of the Reoffer Prospectus, by each of the selling security holders, and any other person
  with whom he or she is acting in concert for the purpose of selling our shares of Common Stock, may not exceed, during any three month
  period, the amount specified in Rule 144(e) of the Securities Act.
  Unless otherwise indicated, all share amounts and share prices disclosed herein are presented on a post-split basis, giving effect to
  the one-for-forty (1:40) reverse stock split (the "Reverse Stock Split") of all of the outstanding shares of the Company's
  issued and outstanding Common Stock on September 24, 2024. Any financial statements incorporated by reference into this prospectus that
  were filed prior to the Reverse Stock Split present the outstanding shares on a pre-split basis. Financial statements filed after September
  24, 2024 retroactively present the shares on a post-split basis.
  PART
  I
  INFORMATION
  REQUIRED IN THE SECTION 10(a) PROSPECTUS
  Item
  1. Plan Information.*
  Item
  2. Registrant Information and Employee Plan Annual Information.*
  *
  Pursuant
                                              to the Note to Part I on Form S-8, the documents containing the information specified in
                                              Part I of this Registration Statement will be sent or given to plan participants as specified
                                              by Rule 428(b)(1) of the Securities Act of 1934, as amended (the "Securities Act").
                                              Such documents are not required to be filed, and are not filed, with the United States Securities
                                              and Exchange Commission either as part of this Registration Statement or as prospectuses
                                              or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and
                                              the documents incorporated by reference in this Registration Statement pursuant to Item 3
                                              of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements
                                              of Section 10(a) of the Securities Act.
  REOFFER
  PROSPECTUS
  Onconetix,
  Inc.
  Up to 371,596 shares
  of Common Stock under the 2022 Equity Incentive Plan
  This
  prospectus relates to the resale of up to 371,596 shares (the "Shares") of common stock, par value $0.00001 per share (the
  "Common Stock"), of Onconetix, Inc., a Delaware corporation (the "Company", "us", "our"
  or "we"), which may be offered and sold from time to time by certain stockholders of the Company (the "Selling Stockholders")
  who have acquired or will acquire such Shares in connection with the exercise of stock options granted, and with stock or other awards
  made, and with the purchase of stock under, the 2022 Plan. The 2022 Plan is intended to provide incentives which will attract, retain,
  and motivate highly competent persons such as officers, employees, directors, and consultants to our Company by providing them opportunities
  to acquire shares of our Common Stock. Additionally, the 2022 Plan is intended to assist in further aligning the interests of our officers,
  employees, directors and consultants to those of the Company's other stockholders.
  The persons who are issued such Shares may include our directors, officers,
  employees and consultants, certain of whom may be considered our "affiliates". Such persons may, but are not required to,
  sell the Shares they acquire pursuant to this prospectus. If any additional awards are issued to or Shares are purchased by affiliates
  under the 2022 Plan, we will file with the Securities and Exchange Commission (the "Commission") an update to this prospectus
  naming such person as a selling shareholder and indicating the number of shares such person is offering pursuant to the prospectus. See
  "Selling Stockholders" on page 12 of this prospectus. Our Common Stock is listed on The Nasdaq Capital Market under the symbol
  "ONCO." On December 9, 2024, the closing price of the Common Stock on The Nasdaq Capital Market was $0.7101 per share.
  Our
  shares of common stock have experienced extreme volatility in market prices and trading volume since listing. The trading price
  of our common stock has been, and may continue to be, subject to wide price fluctuations in response to various factors, many of which
  are beyond our control, including those described under the heading "Risk Factors" beginning on page 10 of this prospectus.
  We
  will not receive any of the proceeds from sales of the Shares by any of the Selling Stockholders. The Shares may be offered from time
  to time by any or all of the Selling Stockholders through ordinary brokerage transactions, in negotiated transactions or in other transactions,
  at such prices as such Selling Stockholder may determine, which may relate to market prices prevailing at the time of sale or be a negotiated
  price. See "Plan of Distribution." Sales may be made through brokers or to dealers, who are expected to receive customary
  commissions or discounts. We are paying all expenses of registration incurred in connection with this offering but the Selling Stockholders
  will pay all brokerage commissions and other selling expenses.
  The
  Selling Stockholders and participating brokers and dealers may be deemed to be "underwriters" within the meaning of the Securities
  Act, in which event any profit on the sale of shares of those Selling Stockholders and any commissions or discounts received by those
  brokers or dealers may be deemed to be underwriting compensation under the Securities Act.
  SEE
  "RISK FACTORS" BEGINNING ON PAGE 10 OF THIS PROSPECTUS FOR A DISCUSSION OF CERTAIN RISKS AND OTHER FACTORS THAT YOU SHOULD
  CONSIDER BEFORE PURCHASING OUR COMMON STOCK.
  Neither
  the Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is
  truthful or complete. Any representation to the contrary is a criminal offense.
  The date of this prospectus is December 10, 2024.
  TABLE
  OF CONTENTS
  Page
      No
  Where
      You Can Find More Information
  ii
  Prospectus
      Summary
  1
  Cautionary
      Note Regarding Forward Looking Statements
  8
  Risk Factors
  10
  Selling Stockholders
  12
  Use of Proceeds
  13
  Plan of Distribution
  13
  Legal Matters
  14
  You
  should rely only on the information contained in or incorporated by reference into this prospectus or any prospectus supplement. We have
  not authorized any person to give any information or to make any representations other than those contained or incorporated by reference
  in this prospectus, and, if given or made, you must not rely upon such information or representations as having been authorized. This
  prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than our shares of Common
  Stock described in this prospectus or an offer to sell or the solicitation to buy such securities in any circumstances in which such
  offer or solicitation is unlawful. You should not assume that the information we have included in this prospectus is accurate as of any
  date other than the date of this prospectus or that any information we have incorporated by reference is accurate as of any date other
  than the date of the document incorporated by reference regardless of the time of delivery of this prospectus or of any securities registered
  hereunder.
  i
  WHERE
  YOU CAN FIND MORE INFORMATION
  The
  Company is subject to the information requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
  and, in accordance therewith, files reports, proxy statements and other information with the Commission. We are required to file electronic
  versions of those materials with the Commission through the Commission's EDGAR system. The Commission maintains an Internet site
  at http://www.sec.gov, which contains reports, proxy and information statements and other information regarding registrants that file
  electronically with the Commission. You can read and copy the reports, proxy statements and other information filed by the Company with
  the Commission at such Internet site.
  This
  prospectus constitutes part of a Registration Statement on Form S-8 filed on the date hereof (herein, together with all amendments and
  exhibits, referred to as the "Registration Statement") by the Company with the Commission under the Securities Act. This
  prospectus does not contain all of the information set forth in the Registration Statement, certain parts of which we have omitted, in
  accordance with the rules and regulations of the Commission. You should refer to the full Registration Statement for further information
  with respect to the Company and our Common Stock.
  Statements
  contained herein concerning the provisions of any contract, agreement or other document are not necessarily complete, and in each instance
  reference is made to the copy of such contract, agreement or other document filed as an exhibit to the Registration Statement or otherwise
  filed with the Commission. Each such statement is qualified in its entirety by such reference. Copies of the Registration Statement together
  with exhibits may be inspected at the offices of the Commission as indicated above without charge and copies thereof may be obtained
  therefrom upon payment of a prescribed fee.
  No
  person is authorized to give any information or to make any representations, other than those contained in this prospectus, in connection
  with the offering described herein, and, if given or made, such information or representations must not be relied upon as having been
  authorized by the Company or any Selling Stockholder. This prospectus does not constitute an offer to sell, or a solicitation of an offer
  to buy, nor shall there be any sale of these securities by any person in any jurisdiction in which it is unlawful for such person to
  make such offer, solicitation or sale. Neither the delivery of this prospectus nor any sale made hereunder shall under any circumstances
  create an implication that the information contained herein is correct as of any time subsequent to the date hereto.
  ii
  PROSPECTUS
  SUMMARY
  The
  SEC allows us to "incorporate by reference" certain information that we file with the SEC, which means that we can disclose
  important information to you by referring you to those documents. The information incorporated by reference is considered to be part
  of this prospectus, and information that we file later with the SEC will update automatically, supplement and/or supersede the information
  disclosed in this prospectus. Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus
  shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus
  or in any other document that also is or is deemed to be incorporated by reference in this prospectus modifies or supersedes such statement.
  Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
  You should read the following summary together with the more detailed information regarding our company, our Common Stock and our financial
  statements and notes to those statements included in this prospectus.
  Our
  Company
  We are a commercial stage
  biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology.
  Through our recent acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate
  cancer originally developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation ("IVDR"),
  which we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with Laboratory Corporation of
  America ("LabCorp").
  We also own ENTADFI, an FDA-approved,
  once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate. However, in light of (i)
  the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company's cash runway and indebtedness,
  the Company determined to pause its commercialization of ENTADFI during the first quarter of 2024, as it explores strategic alternatives
  to monetize ENTADFI, such as a potential sale of the ENTADFI assets. To that end, the Company has been working with an investment advisor
  to assist with a potential sale or other transaction of the ENTADFI assets during the second and third quarters of 2024. There is currently
  no plan to resume commercialization of ENTADFI, and as such, if we are not able to consummate a sale or other transaction of the ENTADFI
  assets, we may abandon the assets and destroy our inventory of the product. In addition, as part of cost reduction efforts and in connection
  with our initial pause in commercializing ENTADFI, we terminated three employees involved with the ENTADFI program, effective April 30,
  2024, with such individuals to continue assisting the Company on an as-needed, consulting basis. Based on the current circumstances surrounding
  ENTADFI, at June 30, 2024, the ENTADFI assets were fully impaired. Refer to Notes 4 and 5 in the accompanying condensed consolidated financial
  statements incorporated by reference in this prospectus for further discussion. The Company continues to search for a permanent Chief
  Executive Officer and Chief Financial Officer.
  We are currently focusing
  our efforts on commercializing Proclarix.
  Proclarix
  is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient's regular Prostate-Specific
  Antigen ("PSA") test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA
  molecules in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many
  other reasons including infections, prostate stimulation, vigorous exercise, or even certain medications. PSA results can be confusing
  for many patients and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant
  resulting in an overdiagnosis and overtreatment that impacts the physician's routine, our healthcare system, and the quality of
  patients' lives. Approximately 10% of all men have elevated PSA levels, commonly referred to as the diagnostic "grey zone",
  of which only 20 – 40% present clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult
  to decide if a biopsy is necessary to verify a potential clinically significant cancer diagnosis.
  Proclarix
  helps doctors and patients with unclear PSA test results through the use of our proprietary Proclarix Risk Score which delivers clear
  and immediate diagnostic support for further treatment decisions. No additional intervention is required, and results are available quickly.
  Local diagnostic laboratories can integrate this multiparametric test into their current workflow because Proclarix assays use the enzyme-linked
  immunosorbent assay (ELISA) standard, which most diagnostic laboratories are already equipped to process.
  Since our inception in October
  2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development,
  undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel,
  acquiring and developing our technology and now halted vaccine candidates, organizing and staffing our company, performing business planning,
  establishing our intellectual property portfolio and raising capital to support and expand such activities.
  1
  During the third quarter of
  2023, we halted our vaccine discovery and development programs, and accordingly, we now operate in one segment: commercial. The commercial
  segment was new in the second quarter of 2023 and is currently dedicated to the development and commercialization of Proclarix.
  Given Proclarix is CE-marked for sale in
  the European Union, we expect to generate revenue from sales of Proclarix by 2026. Although we anticipate these sales to offset some
  expenses relating to commercial scale up and development, we expect our expenses will increase substantially in connection with our ongoing
  activities, as we:
  ●
  commercialize
                                              Proclarix;
  ●
  hire
                                              additional personnel;
  ●
  operate
                                              as a public company; and
  ●
  obtain,
                                              maintain, expand, and protect our intellectual property portfolio.
  We
  rely and will continue to rely on third parties for the manufacturing of Proclarix. We have no internal manufacturing capabilities, and
  we will continue to rely on third parties, of which the main suppliers are single-source suppliers, for commercial products.
  We do not have any products
  approved for sale, aside from Proclarix in the European Union, and ENTADFI, from which we have not generated any revenue from product
  sales, and for which we have now abandoned commercialization activities for. We are exploring strategic alternatives to monetize ENTADFI,
  such as a potential sale of the ENTADFI assets. However, if we are not able to consummate a sale or other transaction of the ENTADFI assets,
  we may abandon the assets and destroy our inventory of the product. To date, we have financed our operations primarily with proceeds from
  our sale of preferred securities to seed investors, the initial public offering, the private placements completed during 2022, the proceeds
  received from a warrant exercise in August 2023, the proceeds received from the issuance of debt in January 2024, the proceeds received
  from a warrant exercise in July 2024, and proceeds received from the private placement in October 2024 . We will continue to require significant
  additional capital to commercialize Proclarix, and to fund operations for the foreseeable future. Accordingly, until such time as we can
  generate significant revenue, if ever, we expect to finance our cash needs through public or private equity or debt financings, third-party
  funding and to rely on third-party resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances
  and licensing arrangements, or any combination of these approaches, to support our operations.
  We have incurred net losses
  since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from
  quarter-to-quarter and year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing
  activities, our expenditures on other research and development activities and commercialization activities. As of September 30, 2024,
  the Company had a working capital deficit of approximately $16.3 million and an accumulated deficit of approximately $86.0 million. In
  addition, as of December 5, 2024, the Company's cash balance was approximately $0.4 million, which is held by the Company's
  foreign subsidiary. The Company believes that its current cash balance is not sufficient to fund its operations through the end of December
  2024, until it can utilize the ELOC, which it entered into in on October 2, 2024, and as such, we will need to raise additional capital
  prior to this to sustain operations. However, based on the terms of the ELOC and the current maximum availability, management has determined
  that the funds readily available under the ELOC will not be sufficient to sustain operations for the next 12 months.
  Until we generate revenue
  sufficient to support self-sustaining cash flows, if ever, we will need to raise additional capital to fund our continued operations,
  including our product development and commercialization activities related to our current and future products. There can be no assurance
  that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide
  self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The condensed
  consolidated financial statements as of and for the nine months ended September 30, 2024 incorporated by reference in this prospectus
  do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.
  2
  Because
  of the numerous risks and uncertainties associated with our business, we are unable to predict the timing or amount of increased expenses
  or when or if we will be able to achieve or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix,
  we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may
  be unable to continue our operations at planned levels and may be forced to reduce our operations.
  Recent
  Developments
  PIPE
  Financing and ELOC
  On
  October 2, 2024, the Company entered into, and sold, to six institutional investors (collectively, the "PIPE Investors"),
  pursuant to a securities purchase agreement an aggregate of 3,499 shares of Series C convertible preferred stock, par value $0.00001 per
  share ("Series C Preferred Stock"), which includes an issuance of 840 shares of Series C Preferred Stock to the lead investor
  in consideration for the PIPE Investors' irrevocable commitment to purchase shares of the Series C Preferred Stock, and warrants
  to purchase 591,856 shares of Common Stock, (together, the "PIPE Securities") for aggregate cash proceeds to the Company of
  $2.0 million and net proceeds of $1.9 million. The exercise price of the warrants is $4.38, and the warrants are exercisable six months
  after the issuance date and expire on the third anniversary of the initial exercisability date.
  On
  October 2, 2024, the Company entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility with
  Keystone
  Capital Partners, LLC ("Keystone")
  , whereby the Company may offer and sell, from time
  to time at its sole discretion, and whereby Keystone has committed to purchase, up to $25.0 million of the Company's newly issued
  Common Stock, subject to certain limitations. Concurrently with entering into the ELOC Purchase Agreement, the Company also entered into
  a registration rights agreement with Keystone, pursuant to which it agreed to provide Keystone with certain registration rights related
  to the shares issued under the ELOC Purchase Agreement (the "ELOC Registration Rights Agreement").
  Reverse
  Stock Split
  On
  September 23, 2024, the Company filed an amendment (the "Amendment") to the Company's Amended and Restated Certificate
  of Incorporation to effect a Reverse Stock Split of all of the outstanding shares of its issued and outstanding Common Stock at a ratio
  of one-for-forty (1:40). The Reverse Stock Split became effective in accordance with the terms of the Amendment at 12:01 a.m. Eastern
  Time on September 24, 2024 (the "Effective Time"). The Company's Common Stock continued to be traded on The Nasdaq
  Capital Market under the symbol ONCO and began trading on a split-adjusted basis when the market opened on Tuesday, September 24, 2024,
  under a new CUSIP number, 68237Q104.
  At
  the Effective Time, every 40 shares of the Company's issued and outstanding Common Stock were converted automatically into one
  issued and outstanding share of Common Stock, with no corresponding reduction in the number of authorized shares of Common Stock, and
  without any change in the par value per share.
  Conversion of Series A Preferred Stock
  On
  September 24, 2024, the Company issued an aggregate of 142,749 post-Reverse Stock Split shares of Common Stock to Veru Inc. ("Veru"),
  following Veru's election to convert all of the 3,000 shares of Series A preferred stock ("Series A Preferred Stock")
  of the Company issued to it on September 29, 2023. The Series A Preferred Stock was originally issued to Veru pursuant to an Amendment
  to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru.
  3
  Conversion
  of Series B Preferred Stock
  On
  September 24, 2024, the Company issued an aggregate of 6,741,820 post-Reverse Stock Split shares of Common Stock to certain stockholders
  of the Company (the "PMX Converted Shares") who were formerly holders of outstanding capital stock or convertible securities
  (the "Sellers") of Proteomedix AG ("Proteomedix"), pursuant to the automatic conversion of all the 2,696,729
  shares of Series B preferred stock ("Series B Preferred Stock") of the Company, which Series B Preferred Stock was originally
  issued to the Sellers on December 15, 2023. The Series B Preferred Stock was originally issued to the Sellers pursuant to a Share Exchange
  Agreement, dated December 15, 2023, between the Company, Proteomedix and the Sellers (the "Share Exchange Agreement"), and
  were subject to automatic conversion following (i) the Company's receipt of stockholder approval for the issuance of the PMX Converted
  Shares and (ii) the effectiveness of the Reverse Stock Split, which provided for a sufficient number of authorized shares to issue the
  PMX Converted Shares, as contemplated by the Share Exchange Agreement.
  Altos
  Units
  On
  September 24, 2024, pursuant to the Subscription Agreement, dated
  December 18, 2023, between
  the Company and Altos Venture AG ("Altos" and such agreement, the "Subscription Agreement"), the Company issued
  an aggregate of 513,424 units (the "Units") to Altos, each Unit comprised of (i) one share of Common Stock and (ii) one pre-funded
  warrant (collectively, the "Altos Warrants") to purchase 0.3 shares of Common Stock at an exercise price of $0.04 per share.
  The Altos Warrants were immediately exercisable at any time on or after the date of issuance and had a term of exercise of five (5) years
  from the date of issuance. Additional shares are issuable to Altos to the extent Altos continues to hold Common Stock included in
  the Units and if the VWAP during the 270 days following closing is less than $10.00, as set forth in the Subscription Agreement.
  On
  September 24, 2024, Altos exercised all of the Altos Warrants, and the Company issued to Altos an additional 154,027 shares of Common
  Stock upon such exercise.
  Veru
  Agreement
  Previously, on April 19,
  2023, the Company entered into an asset purchase agreement with Veru (the "Veru APA"). Pursuant to the terms of the Veru APA,
  the Company agreed to pay to Veru aggregate consideration of $20.0 million, consisting of: (i) $6.0 million paid upon the closing of the
  transaction; (ii) $4.0 million in the form of a non-interest bearing note payable due on September 30, 2023; and (iii) $10.0 million in
  the form of two equal (i.e. each for $5.0 million) non-interest bearing notes payable, which were to be due on April 19, 2024 (the "April
  Veru Note") and September 30, 2024 (the "September Veru Note"), respectively. On September 29, 2023, the parties amended
  (the "Veru Amendment") the Veru APA. Pursuant to the Veru Amendment, the $4.0 million note payable originally due on September
  30, 2023, was deemed paid and fully satisfied upon (1) the payment to Veru of $1 million in immediately available funds on September 29,
  2023, and (2) the issuance to Veru by October 3, 2023, of 3,000 shares of Series A Preferred Stock of the Company.
  On April 24, 2024, the Company
  entered into a Forbearance Agreement with Veru (the "Original Forbearance Agreement"), pursuant to which Veru agreed, among
  other things, to forbear from exercising its rights and remedies under the April Veru Note until March 31, 2025 (the "April 2024
  Forbearance Period").
  On
  September 19, 2024, the Company entered into an Amended and Restated Forbearance Agreement with Veru (the "A&R Forbearance
  Agreement") which amends and restates the Original Forbearance Agreement in its entirety. Pursuant to the A&R Forbearance Agreement,
  Veru will forbear from exercising its rights under both the April Veru Note and the September Veru Note, subject to the terms and conditions
  set forth below.
  Pursuant
  to the A&R Forbearance Agreement, the April 2024 Forbearance Period continues to end on the earlier of (a) March 31, 2025
  and (b) the occurrence of an Event of Default (as defined in the A&R Forbearance Agreement). The A&R Forbearance Agreement
  also extends the due date for the
  September Veru
  Note until the earlier to occur of: (i) June 30, 2025 or (ii) the occurrence of any Event of Default.
  The
  A&R Forbearance Agreement also effected certain modifications to the payment terms in the Original Forbearance Agreement and amended
  certain terms of the September Veru Note as summarized below.
  Pursuant
  to the A&R Forbearance Agreement, the Company agreed to make the following required payments (the "Required Payments")
  during the April 2024 Forbearance Period first to accrued and unpaid interest under the April Veru Note and then any remainder to the
  outstanding principal amount of the April Veru Note:
  ●
  Interest
                                              at the rate of 10% per annum shall accrue on any unpaid principal balance of the April Veru
                                              commencing on April 20, 2024 through the date that the outstanding principal balance under
                                              the April Veru Note is paid in full;
  4
  ●
  monthly
                                              payments equal to 25% (increased from 15% in the Original Forbearance Agreement) of (i) the
                                              monthly cash receipts of Proteomedix for the licensing or sale of any products or services,
                                              (ii) monthly cash receipts of the Company or any of its subsidiaries for the sales of Proclarix
                                              anywhere in the world, and (iii) monthly cash receipts of the Company or any of its subsidiaries
                                              for milestone payments or royalties from Labcorp cash receipts of the Company or its subsidiaries
                                              from certain sale or licensing revenues or payments (the Ordinary Cash Revenue"), which
                                              increased amount shall begin on October 20, 2024 for cash receipts in September 2024;
  ●
  payment
                                              of 20% (increased from 10% in the Original Forbearance Agreement) of the net proceeds from
                                              certain financing or other transactions outside the ordinary course of business completed
                                              by the Company or any of its subsidiaries during the April 2024 Forbearance Period, which
                                              increased amount will begin for any net proceeds received after September 19, 2024;
  ●
  15%
                                              of the Ordinary Cash Revenue generated in August 2024 shall be due to Veru on September 26,
                                              2024 (the "September Veru Payment"); and
  ●
  The
                                              remaining balance of the April Veru Note will be due at the end of the April 2024 Forbearance
                                              Period.
  The
  Company and Veru also agreed to the following amendments to the September Veru Note in the A&R Forbearance Agreement:
  ●
  As
                                              noted above, an extension of the maturity date to June 30, 2025;
  ●
  The
                                              accrual of interest at the rate of 10% per annum on any unpaid principal balance of the September
                                              Veru Note commencing on October 1, 2024 through the date that the outstanding principal balance
                                              under the September Veru Note is paid in full;
  ●
  Any
                                              amounts owed on the September Veru Note, including but not limited to unpaid principal and
                                              accrued interest, will be paid in cash or, upon the mutual written consent of Veru and the
                                              Company, in shares of the Company's Common Stock or a combination of cash and the Company's
                                              Common Stock;
  ●
  Following
                                              full repayment of all principal and interest under the April Veru Note, the Company will
                                              make the Required Payments first towards accrued and unpaid interest under the September
                                              Veru Note and then towards the remaining principal balance payable under the September Veru
                                              Note;
  ●
  If
                                              the aggregate unpaid principal outstanding under the April Veru Note and the September Veru
                                              Note and all accrued and unpaid interest thereon is repaid in cash on or before December
                                              31, 2024, then the total principal balance under the September Veru Note that will be payable
                                              by the Company in satisfaction of its obligations under the September Veru Note will be reduced
                                              from $5,000,000 to $3,500,000.
  On
  September 26, 2024, Veru and the Company entered into a waiver agreement, pursuant to which Veru postponed the Company's obligation
  to make the September Veru Payment until the earlier of (i) the date upon which the Company consummates a financing transaction in which
  it raises gross proceeds of greater or equal to $1,000,000 and (ii) October 4, 2024. The Company paid the September Veru Payment on October
  10, 2024.
  On November 26, 2024, the
  Company and Veru entered into a waiver and amendment to the A&R Forbearance Agreement (the "Amendment"), pursuant to which
  Veru agreed to waive the due date for payment of applicable Cash Receipt Payments (as such term is defined in the A&R Forbearance
  Agreement) generated in October 2024 until the Company receives funds of at least $97,000 pursuant to its equity line of credit facility
  with Keystone Capital Partners LLC. In exchange, the Company agreed to increase its payments to be made to Veru out of future financing
  and strategic transactions through June 30, 2025, from 20% to 25% of net proceeds generated from such transactions.
  5
  Warrant
  Inducement
  On
  July 11, 2024, the Company, entered into common stock preferred investment options exercise inducement offer letters (the "Inducement
  Letter") with certain holders of existing preferred investment options to purchase shares of the Company's common stock at
  the original exercise prices of $101.84 and $43.60 per share, issued on August 11, 2022 and August 2, 2023, respectively, pursuant to
  which the holders agreed to exercise for cash such existing preferred investment options to purchase an aggregate of 186,465 of the Company's
  common stock, at a reduced exercise price of $6.00 per share, in consideration for the Company's agreement to issue new preferred
  investment options (the "PIOs") to purchase up to an aggregate of 559,397 shares of the Company's common stock.
  The
  transaction closed on July 12, 2024 and the Company received aggregate net proceeds of approximately $0.9 million from the exercise of
  the existing preferred investment options by the holders and the sale of the Inducement PIOs, after deducting placement agent fees and
  other offering expenses payable by the Company.
  The
  Company engaged H.C. Wainwright & Co., LLC ("Wainwright") to act as its exclusive placement agent in connection with
  the Warrant Inducement and paid Wainwright a cash fee equal to 7.5% of the gross proceeds received from the exercise of the existing
  preferred investment options as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the existing preferred
  investment options, plus the reimbursement of up to $85,000 in certain expenses. The Company also agreed to (i) issue to Wainwright or
  its designees an aggregate of 13,054 preferred investment options, and (ii) upon any exercise for cash of the Inducement PIOs, 7.5% of
  the aggregate exercise price and such number of warrant to purchase shares of common stock equal to 7.0% of the aggregate number of such
  shares of common stock underlying the Inducement PIOs that have been exercised, which warrants will have substantially the same terms
  as the Placement Agent Inducement PIOs.
  The
  Inducement PIOs have an initial exercise price of $6.00 per share, subject to adjustment; one-third of such preferred investment options
  will expire five years from the date of stockholder approval (September 5, 2024), and the remaining two-thirds will expire twenty-four
  months from such date. The Placement Agent Inducement PIOs have an initial exercise price of $7.50 per share, subject to adjustment,
  and will expire five years from the issuance date.
  In
  addition, per the terms of the Inducement Letter, the Company agreed not to issue any shares of common stock or common stock equivalents
  or to file any other registration statement with the SEC (in each case, subject to certain exceptions) until the later of (i) the filing
  of a definitive proxy statement on Schedule 14A for the purpose of obtaining the requisite stockholder approval and (ii) 30 days after
  the closing date. The Company also agreed not to effect or agree to effect any variable rate transaction (as defined in the Inducement
  Letter) until six months after the closing date (subject to certain exceptions).
  Corporate
  Information
  We
  were incorporated in Delaware on October 26, 2018. Our principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati,
  Ohio 45202, and our telephone number is (513) 620-4101. Our corporate website address is
  www.onconetix.com
  . The information contained
  on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is
  an inactive textual reference only.
  6
  The
  Offering
  Outstanding
      Common Stock:
  8,294,734 shares of our Common Stock are outstanding as of December
  5, 2024.
  Common
      Stock Offered:
  Up to 371,596 shares of Common Stock for sale by the Selling Stockholders (which include our employees, consultants, executive officers
      and directors) for their own account pursuant to the 2022 Plan.
  Selling
      Stockholders:
  The
      Selling Stockholders are set forth in the section entitled "Selling Stockholders" of this reoffer prospectus on page
      12. The amount of securities to be offered or resold by means of the reoffer prospectus by the designated Selling Stockholders
      may not exceed, during any three month period, the amount specified in Rule 144(i).
  Use
      of proceeds:
  We
      will not receive any proceeds from the sale of our Common Stock by the Selling Stockholders. We would, however, receive proceeds
      upon the exercise of the stock options by those who receive options under the Plan and exercise such options for cash. Any cash proceeds
      will be used by us for general corporate purposes.
  Risk
      Factors:
  The
      securities offered hereby involve a high degree of risk. See "Risk Factors."
  Nasdaq
      Capital Market trading symbol:
  ONCO
  7
  CAUTIONARY
  NOTE REGARDING FORWARD-LOOKING STATEMENTS
  This
  prospectus contains "forward-looking statements" within the meaning of the federal securities laws, and that involve significant
  risks and uncertainties. Words such as "may," "should," "could," "would," "predicts,"
  "potential," "continue," "expects," "anticipates," "future," "intends,"
  "plans," "believes," "estimates," and similar expressions, as well as statements in future tense,
  identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and
  may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information
  we have when those statements are made or management's good faith belief as of that time with respect to future events and are
  subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed
  in or suggested by the forward-looking statements. Forward-looking statements are subject to a number of risks, uncertainties and assumptions
  in other documents we file from time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports
  on Form 10-Q and our Current Reports on Form 8-K.
  Important
  factors that could cause such differences include, but are not limited to:
  ●
  our
                                              projected financial position and estimated cash burn rate;
  ●
  our
                                              estimates regarding expenses, future revenues and capital requirements;
  ●
  our
                                              ability to continue as a going concern;
  ●
  our
                                              need to raise substantial additional capital to fund our operations;
  ●
  our
                                              ability to commercialize or monetize Proclarix and integrate the assets and commercial operations
                                              acquired in the share exchange with Proteomedix AG ("Proteomedix");
  ●
  our
                                              reliance on third parties, including Labcorp, to develop, market, distribute and sell our
                                              products;
  ●
  the
                                              successful development of our commercialization capabilities, including sales and marketing
                                              capabilities.
  ●
  our
                                              ability to obtain and maintain the necessary regulatory approvals to market and commercialize
                                              our products;
  ●
  the
                                              results of market research conducted by us or others;
  ●
  our
                                              ability to obtain and maintain intellectual property protection for our current products;
  ●
  our
                                              ability to protect our intellectual property rights and the potential for us to incur substantial
                                              costs from lawsuits to enforce or protect our intellectual property rights;
  8
  ●
  the
                                              possibility that a third party may claim we or our third-party licensors have infringed,
                                              misappropriated, or otherwise violated their intellectual property rights and that we may
                                              incur substantial costs and be required to devote substantial time defending against claims
                                              against us;
  ●
  our
                                              reliance on third parties, including manufacturers and logistics companies;
  ●
  the
                                              success of competing therapies or diagnostics and products that are or become available;
  ●
  our
                                              ability to successfully compete against current and future competitors;
  ●
  our
                                              ability to expand our organization to accommodate potential growth and our ability to attract,
                                              motivate and retain key personnel;
  ●
  the
                                              potential for us to incur substantial costs resulting from product liability lawsuits against
                                              us and the potential for these product liability lawsuits to cause us to limit our commercialization
                                              of our products;
  ●
  market
                                              acceptance of our products, the size and growth of the potential markets for our current
                                              products, and our ability to serve those markets; and
  ●
  disruptions
                                              in the business of the Company or Proteomedix, which could have an adverse effect on their
                                              respective businesses and financial results.
  These
  forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in "
  Risk
  Factors
  ." Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time.
  It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent
  to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking
  statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed
  in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking
  statements.
  You
  should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected
  in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
  and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither
  we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation
  to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual
  results or to changes in our expectations.
  You
  should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration
  statement of which this prospectus forms a part with the understanding that our actual future results, levels of activity, performance
  and events and circumstances may be materially different from what we expect.
  9
  RISK
  FACTORS
  Our
  business involves a high degree of risk and uncertainty, including the following risks and uncertainties:
  Investing
  in our common stock involves a high degree of risk. You should carefully consider the following information about these risks before
  deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business,
  reputation, financial condition, results of operations and future growth prospects, as well as our ability to accomplish our strategic
  objectives. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. Additional
  risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and the
  market price of our common stock.
  There
  is substantial doubt about our ability to continue as a "going concern," and we will require substantial additional funding
  to finance our long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or
  terminate some or all of our products and operations.
  The Company has incurred substantial operating
  losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of September 30, 2024,
  the Company had cash of approximately $0.3 million, a working capital deficit of approximately $16.3 million and an accumulated
  deficit of approximately $86.0 million. In addition, as of December 5, 2024, the Company's cash balance was approximately $0.4 million,
  which is held by the Company's foreign subsidiary, and the Company has approximately $9.8 million of debt due within the next 12
  months.
  We estimate, as of the date of this prospectus,
  that our current cash balance is not sufficient to fund our operations through the end of December, until we can utilize the ELOC. We
  believe that we will need to raise substantial additional capital to fund our continuing operations, satisfy existing and future obligations
  and liabilities, and otherwise support the Company's working capital needs and business activities, including making the remaining
  payments to Veru and the commercialization of Proclarix. Management's plans for funding the Company's operations include generating
  product revenue from sales of Proclarix, which is still subject to further successful development and commercialization activities within
  certain jurisdictions. Management also intends to secure additional required funding through equity or debt financings if available, and
  to utilize the
  ELOC
  on an as-needed basis to assist with the paydown of the debentures and
  to fund current operating needs, subject to certain restrictions and beneficial ownership constraints. However, based on the terms of
  the ELOC and the current maximum availability, management has determined that the funds readily available under the ELOC will not be sufficient
  to sustain operations for the next 12 months. In addition, there are currently no other commitments in place for further financing nor
  is there any assurance that such financing will be available to the Company on favorable terms, if at all. This creates significant uncertainty
  whether the Company will have the funds available to be able to sustain its long-term operations and expand commercialization of Proclarix.
  If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development and/or commercialization
  of future product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient
  to sustain operations and meet its obligations, or, if it is required to, file for bankruptcy.
  These
  conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of time within one
  year from the issuance of the condensed consolidated financial statements. Our future capital requirements will depend on many
  factors, including:
  ●
  the costs of future development and commercialization activities, including product manufacturing, marketing, sales, royalties, and distribution, for Proclarix and other products for which we have received or will receive marketing approval;
  ●
  our
                                              ability to maintain existing, and establish new, strategic collaborations, licensing or other
                                              arrangements and the financial terms of any such agreements, including the timing and amount
                                              of any future milestone, royalty, or other payments due under any such agreement;
  ●
  any
                                              product liability or other lawsuits related to our products;
  ●
  the
                                              expenses needed to attract, hire, and retain skilled personnel;
  ●
  the
                                              revenue, if any, received from commercial sales of Proclarix or other products for which
                                              we may receive marketing approval;
  10
  ●
  the
                                              costs to establish, maintain, expand, enforce, and defend the scope of our intellectual property
                                              portfolio, including the amount and timing of any payments we may be required to make, or
                                              that we may receive, in connection with licensing, preparing, filing, prosecuting, defending,
                                              and enforcing our patents or other intellectual property rights; and
  ●
  the
                                              costs of operating as a public company.
  Our ability to raise additional funds
  will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional funding
  will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional
  capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce, or terminate our business activities.
  We owe a significant amount of money to Veru, which
  funds we do not have. Veru may take action against us to enforce its rights to payment in the future, which could have a material adverse
  effect on us and our operations.
  Due to recent financial constraints,
  the Company may be unable to timely pay amounts due to Veru, from whom we purchased ENTADFI in April 2023. We may not have sufficient
  funds to pay amounts due to Veru in the near term, if at all, including but not limited to $10 million, $5 million of which was due on
  April 19, 2024 and is subject to certain forbearance terms, and $5 million of which was due on September 30, 2024 and is subject to certain
  forbearance terms. On April 24, 2024, Veru agreed to forbear its rights and remedies until March 31, 2025 with respect to, among other
  things, our inability to pay amounts due on April 19, 2024. Additionally, on September 19, 2024 and November 26, 2024, Veru agreed to
  forbear its rights and remedies until June 30, 2025 with respect to, among other things, our inability to certain pay amounts due on September
  30, 2024 and November 20, 2024. However, Veru may take future action against us, including filing legal proceedings against us seeking
  amounts due and interest accrued or attempting to terminate its relationship with us. If Veru were to take legal action against us, we
  may be forced to scale back our business plan and/or seek bankruptcy protection. We may be subject to litigation and damages for our failure
  to pay amounts due to Veru, and may be forced to pay interest and penalties, which funds we do not currently have. We are currently considering
  strategic options for ENTADFI, including a potential sale or abandonment, and plan to seek funding to support our operations, and to pay
  amounts due to Veru, through a combination of equity offerings, debt financing or other capital sources, including potential collaborations,
  licenses, sales, and other similar arrangements, which may not be available on favorable terms, if at all. The sale of additional equity
  or debt securities, if accomplished, may result in dilution to our stockholders. Furthermore, any revenue or financing proceeds that we
  are required to pay to Veru will detract from our ability to use such funds to support our operations.
  Our
  current liabilities are significant, and if those to whom we owe accounts payable, such as Veru, IQVIA or other creditors or vendors,
  were to demand payment, we would be unable to pay.
  As of September 30, 2024, we had
  total current liabilities of approximately $17.4 million, including accounts payable of approximately $4.1 million, accrued expenses of
  approximately $1.3 million, the related party subscription liability of $1.8 million, and approximately $9.8 million (net of discounts)
  related to notes payable, primarily due to Veru. As of the same date, we had cash of only $0.3 million. We are currently considering strategic
  options for ENTADFI, including a potential sale or abandonment, and plan to seek funding to support our operations. However, the level
  of our current liabilities may make it more difficult for us to obtain adequate financing on favorable terms, if at all. If those to whom
  these payments are due were to demand immediate payment, as they are entitled to do, and we are not able to make the required payments,
  we would be subject to liability if our creditors chose to enforce their rights, which could result in our bankruptcy and insolvency.
  Under such a scenario, our assets would be distributed to our creditors, leaving nothing to be distributed to our stockholders.
  We
  are dependent on third parties, including Labcorp, to develop market, distribute and sell our products.
  Our
  ability to receive revenues is dependent upon the sales and marketing efforts of co-marketing partners and third-party distributors.
  In particular, the development and commercialization of Proclarix in the United States is being pursued by Labcorp, pursuant to an exclusive
  license agreement that grants Labcorp the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp
  using Proteomedix's intellectual property covered by the license, in the United States for identification, screening, staging,
  predisposition, diagnosis, prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. However, we do not
  have control over Labcorp's development and commercialization of Proclarix, and there can be no guarantee that Labcorp will continue
  to advance development and commercialization efforts, or that Labcorp will successfully commercialize Proclarix in the United States.
  Labcorp
  may terminate or seek to renegotiate the terms of this agreement, which could adversely affect our business operations and financial
  condition. If Labcorp terminates the agreement or demands terms that are less favorable to us, we may experience disruptions in our product
  development and commercialization efforts, potentially leading to a loss of revenue and market share.
  Additionally,
  if Labcorp is unable to commercialize Proclarix in the United States, and we fail to reach an agreement with any other commercialization
  partner, or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact
  on our business, financial condition, and results of operations.
  11
  SELLING
  STOCKHOLDERS
  The
  following table sets forth (a) the name and position or positions with the Company of each Selling Stockholder; (b) the aggregate of
  (i) the number of shares of Common Stock held by each Selling Stockholder as of the date of this prospectus and (ii) the number of shares
  issuable upon exercise of options granted to each Selling Stockholder under the 2022 Plan that are being registered pursuant to this
  Registration Statement for resale by each Selling Stockholder as of the date of this prospectus; (c) the number of shares of Common Stock
  issuable upon exercise of options that each Selling Stockholder may offer for sale from time to time pursuant to this prospectus, whether
  or not such Selling Stockholder has a present intention to do so; and (d) the number of shares of Common Stock to be beneficially owned
  by each Selling Stockholder following the sale of all shares that may be so offered pursuant to this prospectus, assuming no other change
  in ownership of Common Stock by such Selling Stockholder after the date of this prospectus. Unless otherwise indicated, beneficial ownership
  is direct and the person indicated has sole voting and investment power.
  The
  Selling Stockholders may, from time to time, resell all, a portion or none of the shares of our Common Stock covered by this reoffer
  prospectus.
  Inclusion
  of an individual's name in the table below does not constitute an admission that such individual is an "affiliate"
  of the Company.
  Selling Stockholder
  Principal
  Position with
  the Company
  Shares Owned
  Prior to Resale
  Number of
  Shares
  Offered
  Shares Beneficially Owned
  After Resale
  Number (1)
  Percent (2)
  for Resale
  Number
  Percent (3)
  Ralph Schiess
  Interim Chief Executive Officer,
  Chief Science Officer
  672,967
  (3)
  7.9
  %
  177,464
  495,503
  6.0
  %
  Christian Brühlmann
  Chief Strategy Officer
  611,374
  (4)
  7.2
  %
  177,464
  433,910
  5.2
  %
  Simon Tarsh
  Director
  3,578
  (5)
  *
  3,318
  —
  260
  Timothy Ramdeen
  Director
  3,536
  (6)
  *
  3,318
  —
  218
  James Sapirstein
  Director
  4,741
  (7)
  *
  3,318
  —
  1,423
  Thomas Meier
  Director
  3,318
  (8)
  *
  3,318
  —
  —
  Ajit Singh
  Director
  3,396
  (9)
  *
  3,396
  —
  —
  *
  Less
                                              than 1%.
  (1)
  The
                                              number of shares owned prior to resale by each Selling Stockholder shares of Common Stock
                                              owned on or about the date hereof by the Selling Stockholders and shares of Common Stock
                                              that are issued or to be issued, or which may be acquired upon the exercise of stock options
                                              issued or to be issued, or vesting of restricted stock awards issued or to be issued, pursuant
                                              to the 2022 Plan.
  (2)
  Percentage is computed with reference to 8,294,734 shares of our Common Stock outstanding as of December 5, 2024. In addition, we deemed outstanding shares of Common Stock subject to options or warrants held by each person for purposes of computing the percentage of ownership for such person. However, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person.
  (3)
  Includes 177,464 restricted stock units.
  (4)
  Includes 177,464 restricted stock units.
  (5)
  Includes (i) options to purchase 101 shares of Common Stock and (ii) 3,318 shares of restricted stock that vest on August 31, 2025.
  (6)
  Includes (i) options to purchase 59 shares of Common Stock and (ii) 3,318 shares of restricted stock that vest on August 31, 2025.
  (7)
  Includes (i) options to purchase 1,264 shares of Common Stock (929 of which are vested within 60 days of December 5, 2024 and (ii) 3,318 shares of restricted stock that vest on August 31, 2025.
  (8)
  Includes 3,318 shares of restricted stock that vest on August 31, 2025.
  (9)
  Includes 3,318 shares of restricted stock that vest on August 31, 2025.
  The
  Company may supplement this prospectus from time to time as required by the rules of the Commission to include certain information concerning
  the security ownership of the Selling Stockholders or any new Selling Stockholders, the number of securities offered for resale and the
  position, office or other material relationship which a Selling Stockholder has had within the past three years with the Company or any
  of its predecessors or affiliates.
  12
  USE
  OF PROCEEDS
  We
  will not receive any proceeds from the resale of our Common Stock by the Selling Stockholders pursuant to this prospectus. However, we
  will receive the exercise price of any Common Stock issued to the Selling Stockholders upon cash exercise by them of their options. We
  would expect to use these proceeds, if any, for general working capital purposes. We have agreed to pay the expenses of registration
  of these shares.
  PLAN
  OF DISTRIBUTION
  In
  this section of the prospectus, the term "Selling Stockholder" means and includes:
  ●
  the
      persons identified in the table above as the Selling Stockholders;
  ●
  those
      persons whose identities are not known as of the date hereof but may in the future be eligible to receive options under the 2022
      Plan; and
  ●
  any
      of the donees, pledgees, distributees, transferees or other successors in interest of those persons referenced above who may: (a)
      receive any of the shares of our Common Stock offered hereby after the date of this prospectus and (b) offer or sell those shares
      hereunder.
  The
  shares of our Common Stock offered by this prospectus may be sold from time to time directly by the Selling Stockholders. Alternatively,
  the Selling Stockholders may from time to time offer such shares through underwriters, brokers, dealers, agents or other intermediaries.
  The Selling Stockholders as of the date of this prospectus have advised us that there were no underwriting or distribution arrangements
  entered into with respect to the Common Stock offered hereby. The distribution of the Common Stock by the Selling Stockholders may be
  effected: in one or more transactions that may take place on The Nasdaq Capital Market (including one or more block transactions) through
  customary brokerage channels, either through brokers acting as agents for the Selling Stockholders, or through market makers, dealers
  or underwriters acting as principals who may resell these shares on The Nasdaq Capital Market; in privately-negotiated sales; by a combination
  of such methods; or by other means. These transactions may be effected at market prices prevailing at the time of sale, at prices related
  to such prevailing market prices or at other negotiated prices. Usual and customary or specifically negotiated brokerage fees or commissions
  may be paid by the Selling Stockholders in connection with sales of our Common Stock.
  The
  Selling Stockholders may enter into hedging transactions with broker-dealers in connection with distributions of the shares or otherwise.
  In such transactions, broker-dealers may engage in short sales of the shares of our Common Stock in the course of hedging the positions
  they assume with the Selling Stockholders. The Selling Stockholders also may sell shares short and redeliver the shares to close out
  such short positions. The Selling Stockholders may enter into option or other transactions with broker-dealers which require the delivery
  to the broker-dealer of shares of our Common Stock. The broker-dealer may then resell or otherwise transfer such shares of Common Stock
  pursuant to this prospectus.
  At
  the time a particular offering of shares of our Common Stock is made, a prospectus supplement, if required, will be distributed, which
  will set forth the name of the Selling Stockholders, the aggregate amount of shares of our Common Stock being offered and the terms of
  the offering, including, to the extent required, (1) the name or names of any underwriters, broker-dealers or agents, (2) any discounts,
  commissions and other terms constituting compensation from the Selling Stockholders and (3) any discounts, commissions or concessions
  allowed or reallowed to be paid to broker-dealers.
  13
  The
  Selling Stockholders also may lend or pledge shares of our Common Stock to a broker-dealer. The broker-dealer may sell the shares of
  Common Stock so lent, or upon a default the broker-dealer may sell the pledged shares of Common Stock pursuant to this prospectus.
  The
  Selling Stockholders will act independently of us in making decisions with respect to the timing, manner, and size of each resale or
  other transfer. There can be no assurance that the Selling Stockholders will sell any or all of the shares of our Common Stock under
  this prospectus. Further, we cannot assure you that the Selling Stockholders will not transfer, distribute, devise or gift the shares
  of our Common Stock by other means not described in this prospectus. In addition, any Shares covered by this prospectus that qualify
  for sale under Rule 144 of the Securities Act may be sold under Rule 144 rather than under this prospectus.
  The
  Selling Stockholders have advised us that they have not entered into any agreements, understandings or arrangements with any underwriters
  or broker-dealers regarding the sale of their securities. There is no underwriter or coordinating broker acting in connection with the
  proposed sale of shares of Common Stock the Selling Stockholders.
  Although
  the shares of Common Stock covered by this prospectus are not currently being underwritten, the Selling Stockholders or their underwriters,
  brokers, dealers or other agents or other intermediaries, if any, that may participate with the selling security holders in any offering
  or distribution of Common Stock may be deemed "underwriters" within the meaning of the Securities Act and any profits realized
  or commissions received by them may be deemed underwriting compensation thereunder.
  Under
  applicable rules and regulations under the Exchange Act, any person engaged in a distribution of shares of the Common Stock offered hereby
  may not simultaneously engage in market making activities with respect to the Common Stock for a period of up to five days preceding
  such distribution. The Selling Stockholders will be subject to the applicable provisions of the Exchange Act and the rules and regulations
  promulgated thereunder, including without limitation Regulation M, which provisions may limit the timing of purchases and sales by the
  Selling Stockholders.
  In
  order to comply with certain state securities or blue sky laws and regulations, if applicable, the Common Stock offered hereby will be
  sold in such jurisdictions only through registered or licensed brokers or dealers. In certain states, the Common Stock may not be sold
  unless they are registered or qualified for sale in such state, or unless an exemption from registration or qualification is available
  and is obtained.
  We
  will bear all costs, expenses and fees in connection with the registration of the Common Stock offered hereby. However, the Selling Stockholders
  will bear any brokerage or underwriting commissions and similar selling expenses, if any, attributable to the sale of the shares of Common
  Stock offered pursuant to this prospectus. We have agreed to indemnify the Selling Stockholders against certain liabilities, including
  liabilities under the Securities Act, or to contribute to payments to which any of those security holders may be required to make in
  respect thereof.
  LEGAL
  MATTERS
  The
  validity of the securities being offered herein has been passed upon for us by Ellenoff Grossman & Schole LLP, New York, New York.
  14
  DISCLOSURE
  OF COMMISSION POSITION ON
  INDEMNIFICATION
  FOR SECURITIES LAWS VIOLATIONS
  Section
  145 of the DGCL inter alia, empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made
  a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation)
  by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the
  request of the corporation as a director, officer, employee or agent of another corporation or other enterprise, against expenses (including
  attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such
  action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests
  of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
  Similar indemnity is authorized for such persons against expenses (including attorneys' fees) actually and reasonably incurred
  in connection with the defense or settlement of any such threatened, pending or completed action or suit if such person acted in good
  faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and provided further that
  (unless a court of competent jurisdiction otherwise provides) such person shall not have been adjudged liable to the corporation. Any
  such indemnification may be made only as authorized in each specific case upon a determination by the stockholders or disinterested directors
  or by independent legal counsel in a written opinion that indemnification is proper because the indemnitee has met the applicable standard
  of conduct.
  Section
  145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee
  or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
  corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his
  status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145. We maintain policies
  insuring our officers and directors against certain liabilities for actions taken in such capacities, including liabilities under the
  Securities Act.
  Section
  102(b)(7) of the DGCL permits a corporation to include in its certificate of incorporation a provision eliminating or limiting the personal
  liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, provided
  that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director's duty of loyalty
  to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing
  violation of law, (iii) under Section 174 of the DGCL (relating to unlawful payment of dividends and unlawful stock purchase or redemption)
  or (iv) for any transaction from which the director derived an improper personal benefit.
  Article
  6 of the bylaws of the Company contains provisions which are designed to provide mandatory indemnification of directors and officers
  of the Company to the full extent permitted by law, as now in effect or later amended. The bylaws further provide that, if and to the
  extent required by the DGCL, an advance payment of expenses to a director or officer of the Company that is entitled to indemnification
  will only be made upon delivery to the Company of an undertaking, by or on behalf of the director or officer, to repay all amounts so
  advanced if it is ultimately determined that such director is not entitled to indemnification.
  15
  You
  should rely only on the information contained in this document. We have not authorized anyone to provide you with information that is
  different. This document may only be used where it is legal to sell these securities. The information in this document may only be accurate
  on the date of this document.
  Additional
  risks and uncertainties not presently known or that are currently deemed immaterial may also impair our business operations. The risks
  and uncertainties described in this document and other risks and uncertainties which we may face in the future will have a greater impact
  on those who purchase our common stock. These purchasers will purchase our common stock at the market price or at a privately negotiated
  price and will run the risk of losing their entire investment.
  ONCONETIX,
  INC.
  371,596 Shares of
  Common
  Stock
  PROSPECTUS
  December 10, 2024
  PART
  II
  INFORMATION
  REQUIRED IN THE REGISTRATION STATEMENT
  Item
  3. Incorporation of Documents by Reference.
  The
  following documents filed with the Commission by the Registrant pursuant to the Securities Act and the Securities Exchange Act of 1934,
  as amended (the "Exchange Act"), are hereby incorporated by reference in this registration statement:
  ●
  our
                                              Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2023, as filed with the
                                              SEC on April 11, 2024
  ●
  our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on
  May 20, 2024
  , for the quarter ended June 30, 2024, as filed with the SEC on
  August 29, 2024
  and for the quarter ended September 30, 2024, as filed with the SEC on
  December 10, 2024
  ;
  ●
  Current
  Reports on Form 8-K filed on each of
  January
  12, 2024
  ,
  January 19, 2024
  ,
  January 29, 2024
  ,
  February
  12, 2024
  ,
  February 13, 2024
  ,
  February 27, 2024
  ,
  April
  8, 2024
  ,
  April 26, 2024
  ,
  May 13, 2024
  ,
  June
  13, 2024
  ,
  June 14, 2024
  ,
  July 11, 2024
  ,
  July
  15, 2024
  ,
  August 7, 2024
  ,
  September 3, 2024
  ,
  September
  5, 2024
  ,
  September 11, 2024
  ,
  September 20, 2024
  ,
  September
  24, 2024
  ,
  October 3, 2024
  ,
  October 9, 2024
  ,
  October
  21, 2024
  and
  December 3, 2024
  ;
  ●
  our
  Definitive Proxy Statement
  , as filed with the SEC on August 1, 2024, and the
  supplemental proxy materials
  filed with the SEC on September 3, 2024; and
  ●
  the
                                              description of our securities registered under Section 12 of the Exchange Act as filed as
  Exhibit 4.2
  on our Annual Report on
  Form 10-K
  for the year ended December 31, 2023, as filed
                                              with the SEC on April 11, 2024.
  All
  documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of
  this registration statement (except for any portions of the Registrant's current reports on Form 8-K furnished pursuant to Item
  2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective
  amendment to this registration statement indicating that all securities offered have been sold or which deregisters all securities then
  remaining unsold, shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date
  of filing of such documents.
  Any
  statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
  for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document
  which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified
  or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
  II-
  1
  Item
  8. Exhibits.
  The
  following exhibits are filed as part of this registration statement:
  Incorporated
      by Reference
  Exhibit
      No.
  Description
  Form
  Exhibit
  Filing
      Date
  4.1
  Specimen Common Stock Certificate.
  S-1
  4.1
  October
      8, 2021
  4.2
  Description of Registered Securities.
  10-K
  4.2
  April
      11, 2024
  4.3
  Certificate of Designation of Series A Preferred Stock.
  8-K
  3.1
  October
      3, 2023
  4.6
  Form of Inducement PIO.
  8-K
  4.1
  July
      11, 2024
  4.7
  Form of Altos Warrants.
  8-K
  4.1
  September 24, 2024
  4.8
  Form of Warrant.
  8-K
  4.1
  October
      3, 2024
  4.9
  Certification of Designation of Series C Preferred Stock.
  8-K
  3.1
  October
      3, 2024
  5.1*
  Opinion of Ellenoff Grossman & Schole LLP as to the legality of the securities being registered.
  10.2
  2022 Equity Incentive Plan.
  S-1/A
  10.2
  November
      29, 2021
  10.4
  2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).
  S-1/A
  10.4
  January
      6, 2022
  10.5
  2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).
  S-1/A
  10.5
  January
      6, 2022
  10.6
  2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).
  S-1/A
  10.6
  January
      6, 2022
  10.7
  2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).
  S-1/A
  10.7
  January
      6, 2022
  23.1*
  Consent of CBIZ CPAs P.C.
  23.2*
  Consent of EisnerAmper LLP.
  23.3*
  Consent of BDO AG.
  23.4*
  Consent of Ellenoff Grossman & Schole (included as part of Exhibit 5.1 hereto).
  24*
  Power of Attorney (included on signature page to this Registration Statement).
  107*
  Filing Fee Table.
  *
  Filed
                                              herewith.
  II-
  2
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the
  requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
  duly authorized, on December 10, 2024.
  ONCONETIX,
      INC.
  By:
  /s/
      Dr. Ralph Schiess
  Dr.
      Ralph Schiess
  Interim
      Chief Executive Officer
  POWER
  OF ATTORNEY
  KNOW
  ALL MEN BY THESE PRESENTS
  , that we, the undersigned officers and directors of Onconetix, Inc., a Delaware corporation, do hereby
  constitute and appoint each of Dr. Ralph Schiess and Karina Fedasz as his or her true and lawful attorney-in-fact and agent, with full
  power of substitution and re-substitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all
  amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement
  and any subsequent registration statement filed by the registrant pursuant to Rule 462(b) of the Securities Act of 1933, as amended,
  which relates to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith,
  with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform
  each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might
  or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may
  lawfully do or cause to be done by virtue hereof.
  Pursuant
  to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
  and on the dates indicated.
  Signature
  Title
  Date
  /s/ Ralph Schiess
  Interim Chief Executive Officer
  December 10, 2024
  Ralph Schiess
  (Principal Executive Officer)
  /s/ Karina M. Fedasz
  Interim Chief Financial Officer
  December 10, 2024
  Karina M. Fedasz
  (Principal Financial and Accounting Officer)
  /s/ James Sapirstein
  Chairman of the Board and Director
  December 10, 2024
  James Sapirstein
  /s/ Thomas Meier
  Director
  December 10, 2024
  Thomas Meier
  /s/ Timothy Ramdeen
  Director
  December 10, 2024
  Timothy Ramdeen
  /s/ Ajit Singh
  Director
  December 10, 2024
  Ajit Singh
  /s/ Simon Tarsh
  Director
  December 10, 2024
  Simon Tarsh
  II-
  3